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ABSTRACT
NUTRITIONAL TRANSPORTER MEDIATED DRUG DELIVERY FOR CANCER
SIDDHARTH S. KESHARWANI
2019
Recent advancements in nanotechnology have unfolded novel opportunities in
medicine, especially in targeted therapeutics and imaging for cancer. However, the
majority of the existing nanotechnologies for cancer suffer from shortcomings such as (i)
rapid elimination from the systemic circulation before reaching the cancer tissue. (ii) poor
tumor accumulation, targeting, and penetration due to inadequate vasculature and extensive
extracellular matrix in the tumor. Thus, overcoming these two limitations of
nanotechnology is of considerable interests for cancer researchers.
In this dissertation, we demonstrate the feasibility of glucose-modified
nanoparticles (GLU-NPs) as an efficient cancer targeted-delivery system for enhancing the
systemic circulation time and tumor accumulation.
In chapter II, using a natural physiological interaction between glucose on the
GLU-NPs and the surface glucose transporter GLUT1 on the RBCs, we have demonstrated
the enhancement of systemic circulation time and thereby, improved tumor accumulation.
GLU-NPs interaction with GLUT1 is non-covalent, reversible and importantly, established
in-vivo. GLU-NPs enhanced the circulation time by hitchhiking on RBCs and reducing
opsonization.
In chapter III, we have demonstrated the ability of GLU-NPs to differentiate breast
cancer versus noncancer cells based on the expression levels of GLUT1. GLUT1 is

xvi
overexpressed in multiple cancer types, and the level of expression is correlated with the
invasiveness of cancer. GLU-NPs were able to deliver significantly large amounts of
encapsulated cargo to breast cancer cells potentially through caveolae-mediated
endocytosis. The in-vivo tumor imaging results depict that the GLU-NPs highly
accumulated into tumors compared to state-of-art technology PEGylation.
In summary, we have demonstrated the ability of GLU-NPs as a smart drug delivery
system for in-vivo enhancement of systemic circulation time and tumor accumulation,
which will have applications beyond cancer therapy and imaging, such as sustained drug
delivery and targeting to other organs.
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CHAPTER I

INTRODUCTION
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1.1. Cancer: Current Therapies and Challenges
Cancer, the second leading cause of mortalities in the United States (US), is a
heterogeneous group of diseases involving complex molecular alterations at the cellular
level and the exact causes of which are difficult to deduce [1, 2]. It occurs in a wide range
of tissues with different outcomes. For example, in the US, there are approximately 200
types of cancers, with lung, breast, prostate and colon cancer accounting for the majority
of the mortalities. The number of cancer patients being diagnosed is expected to be doubled
by the next two decades [1-4]. One out of three people will develop malignancies in their
lifetime, with half of the people diagnosed with cancer dying within the five years of the
occurrence of the disease [5]. It is predicted that approximately 1.5-1.9 million new cancer
cases will be diagnosed in the U.S. in 2019 [1-5].
The current clinical management of cancer involves surgery, radiotherapy,
chemotherapy, targeted drug therapies and more recently immunotherapy and gene
therapy. Chemotherapy has been widely utilized for the clinical management of cancer
mainly affecting cell cycle arrest and/or apoptosis [6-8]. The clinical therapy of cancer
using traditional drugs is not satisfactory due to their high toxicity and occurrence of drug
resistance [3, 4, 9, 10]. Chemotherapy fails to distinguish between normal and cancer
tissues to a significant level to avoid severe toxicity [11, 12]. One of the primary goals of
the current research in cancer therapeutics is to either identify cancer-specific targets
(targeted therapies) or to deliver the chemotherapeutic drugs specifically to the cancer cells
(targeted drug delivery) [13, 14]. Discovering new cancer targets and developing new
drugs that specifically act on these targets is an expensive, time-consuming and
cumbersome process [15, 16]. This is further complicated by the high mutation rates of
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cancer cells that quickly alter the drug target to develop drug resistance [12, 17-20].
However, several barriers to cancer drug delivery complicate the efforts for targeted drug
delivery [21]. Figure 1-1 provides various biological, physiological, physiochemical, and
clinical barriers towards the development of therapeutics to cancers. Nanomedicine
provides unique advantages in overcoming some of the listed challenges for cancer drug
delivery [9, 10, 17, 22-30].

Biological barriers

Physiological barriers

•
•
•
•

•
•
•
•

Cellular membrane
Vascular endothelium
Perivascular space
Blood brain barrier

Drug efflux pumps
Renal filtration
High tumor cell density
Interstitial fluid pressure

Barriers for
drug delivery
to cancer

Physicochemical barriers
• Low solubility and stability
• Large volume of distribution
• Low molecular weight

Clinical barriers
• Low efficacy
• High toxicity
• Need for repeated
administration

Figure 1-1: Various biological, physiological, physiochemical, and clinical barriers
towards the delivery of therapeutics to cancers [17, 28, 30].

4
1.2. Nanomedicine and its Application for Cancer-targeted Drug Delivery
Effective drug delivery is a critical factor in developing treatments for cancer. Restricted
accessibility to tumor tissues due to excess extracellular matrix, poor vasculature along
with the limited systemic circulation time, and non-specific distribution of anti-cancer
drugs poses a unique challenge to deliver therapeutic levels of cancer drugs to the target
tissues. Inefficient delivery of anti-cancer drugs lead to poor tumor response, causes severe
side effects, and promotes the development of cancer drug resistance. Due to the
development of drug resistance, drugs that show favorable initial response are often
rendered ineffective following repeated administrations, and the relapsed cancer becomes
much more difficult to treat. Furthermore, due to the cytotoxic nature of chemotherapeutic
drugs on both cancer and healthy cells, the drug dosage should be restricted to cancer cells
to avoid adverse effects on healthy cells [6, 7, 9, 10, 13, 14, 17, 22-25, 28, 31-33]. To
effectively treat cancers and minimize the effect of developing resistance, high doses of
potent therapeutics are needed to be safely delivered to cancer sites. Nanotechnology offers
unique physical and chemical properties that are beneficial in the targeted delivery of
chemotherapeutic agents to the cancer tissue.
Nanotechnology is at the forefront of drug delivery research, providing innovative
approaches for the diagnosis, treatment, prevention and the management of various
diseases, including cancer [3, 4, 22, 26, 34]. Nanotechnology provides nanoscale drug
delivery vehicles including organic, polymeric, metallic and solid–lipid nanoparticles,
micelles, liposomes, dendrimers, etc. Several of these are either currently approved or
undergoing investigations for the delivery of a variety of small and macromolecular drugs
[28, 34]. Nanoparticles (NPs) are 1-100 nm in diameter; however, submicron particles are
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also often included in this category. Nanocarriers provide unique advantages for cancer
drug delivery such as improved cancer targeting, reduced non-specific cellular uptake,
controlled drug release, ability to carry multiple drugs, protection of the cargo
(drugs/imaging agents) from the adverse biological environments during their transit and
delivery to cancer tissues [33].
Characteristics of an ideal cancer-targeted nanomedicine: [17, 28, 30]
i. An ability to carry therapeutic levels of the drug.
ii. Provide an injectable form (intravenous) for a poorly soluble drug either by improving
its solubility or dispersibility.
iii. Biodegradable and biocompatible.
iv. Avoid premature clearance from the circulation.
v. Minimal drug leakage from the nanocarrier during its transit to the target tissue.
vi. Protect the drug from degradation during storage and transit to the target after injection.
vii. Increase the localization of the drug to the target tissue while minimizing off-target
distribution/toxicity (drug targeting).
viii. Enhance cellular uptake and promote intracellular trafficking to deliver the drug to the
target molecule.
ix. Low rate of aggregation (physical stability).
In nanomedicine, targeting refers to designing nanocarriers that take advantage of the
differences between cancer and the normal cells, with the intention of increasing the
accumulation and penetration in cancer tissues as compared to healthy tissues. There are
two different ways for the delivery of drugs: passive targeting (nanomedicine equipped
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without any targeting ligand) and active targeting (nanomedicine equipped with a targeting
ligand) [14, 28, 30, 31, 33, 35-38].

1.2.1. Passive Targeting to Cancer
Passive targeting essentially refers to preferential accumulation of drug/nanomedicine in
the cancer tissues due to the unique physicochemical properties of nanomedicine combined
with the altered anatomical structures in cancer contributing to enhanced permeation and
retention (EPR effect) [17, 30, 32, 33, 39].
1.2.1.1. Enhanced Permeability and Retention (EPR) Effect
The normal tissues are characterized by continuous capillaries with the small pore radii
being 6-7 nm and the large pore radii being 20-28 nm. To serve the needs of the rapidly
growing cancerous tissues, through the release of vascular endothelial growth factor
(VEGF) and other factors by the cancer cells, rapid vascularization is promoted. Such rapid
vascularization often leads to a leaky and defective vascular architecture devoid of the
basement membrane and impaired lymphatic drainage. The abnormal fenestrations in the
cancer vasculature allow nanocarriers to leak into cancerous tissues, sparing the normal
tissues [40, 41]. Since cancer tissues lack a well-developed lymphatic drainage capability,
NPs that enter are retained within the tissues for prolonged periods of time. This
phenomenon is called as the enhanced permeability and retention (EPR) effect and
Matsumura et al. were the first to describe it [42].
EPR effect is applicable to all solid tumors. It is observed in almost all types of
human cancers with the exception of prostate and pancreatic cancer [17]. Passive targeting
through EPR effect is seen in small and well-vascularized cancers; however, accumulation
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is often inadequate in poorly vascularized cancer tissues. Moreover, vessel permeability
might differ within a single solid tumor, resulting in non-uniform drug profusion and
incomplete cancer treatment. Moreover, passive targeting suffers from certain limitations
such as: (i) the extent of passive targeting depends on angiogenesis and the degree of tumor
vasculature which usually varies between patients and the tumor types. (ii) In the case of
solid tumors, the high interstitial fluid pressure avoids the entry and homogeneous drug
distribution into the tumors [43, 44].
To exploit the EPR effect, it requires the NPs to have a specific size range and shape
(physiochemical properties). In addition, the NPs must be in circulation for a significant
duration for them to pass through leaky vasculature of cancer. However, the immune
system perceives exogeneous NPs as foreign and eliminates them quickly through
mononuclear phagocytic systems (MPS). Studies in mouse xenograft have shown that the
vasculature can permit extravasation of particles 10-200 nm in diameter with limited
studies showing EPR effect up to 500 nm in diameter [45, 46]. Various approaches have
been reported to enhance the circulation time of NPs, which is discussed in detail in section
1.4. We have also addressed this challenge through a unique approach using red blood cells
(chapter II). Some of the clinically approved nanomedicine technologies using passive
targeting are listed in Table 1-1.
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Table 1-1: List of clinically approved passively targeted nanomedicines [35].
Nanocarrier

Name
Doxil®

Drug
Doxorubicin

Indication/Cancer

References

Breast, ovarian,

[47]

Kaposi sarcoma and
multiple myeloma
Myocet®

Doxorubicin

Breast

Onco-TCS®

Vincristine

Non-Hodgkin

[48, 49]

lymphoma
Liposomes

DaunoXome® Daunorubicin Kaposi sarcoma

[50]

DepoCyt®

[51]

Cytosine

Neoplastic

Arabinoside

meningitis

(cytarabine)
Marqibo®

Vincristine

Acute lymphoid

[52]

leukemia
Mepact®

Mifamurtide

Osteosarcoma

[53, 54]

Abraxane®

Albumin-

Breast, pancreatic

[49]

paclitaxel

and non-small cell

Nanoparticles

Micelles

PEG-Lasparaginase

lung cancer
Transdrug®

Doxorubicin

Hepatocarcinoma

Genexol-

Paclitaxel

Breast, lung and

PM®
Oncaspar®

[55]

ovarian cancer
Asparagine

Acute

specific

lymphoblastic

enzyme

leukemia

[56]
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1.3. Active Targeting to Cancer
Active targeting involves attachment of a ligand that acts as a homing device for
nanomedicine that binds with high affinity to proteins (receptors) that are over-expressed
on the diseased tissues such as cancer compared to healthy tissues [17, 30, 32, 33, 39]. It
is also known as ligand-mediated or receptor-mediated targeting. Active targeting
includes three components: drug, delivery system (NPs), and the targeting ligand. The drug
is often encapsulated or conjugated to the delivery system. The targeting ligand is attached
on the surface of the NPs by covalent or non-covalent interactions. Targeting ligands
include biological molecules such as folic acid, carbohydrates, antibodies, antibody
fragments, aptamers, oligonucleotides and peptides, etc. (Table 1-2). Multiple targeting
ligands could be attached to enable multivalent targeting, thus enhancing the binding
efficiency and overcoming the mutations in the targets. This has been termed as
“synaphic” targeting. There is enhanced cellular internalization in case of actively targeted
nanomedicine rather than increased accumulation as observed in passive targeting.
The most common approach in the preparation of actively targeted NPs takes
advantage of well-known molecular recognition in the antibody-antigen binding. For
example, human epidermal growth factor receptor 2 (HER-2) is highly overexpressed in a
certain population of breast cancers [57, 58-60]. Liposomes conjugated with antibodies to
HER-2 yielded 700-fold higher drug uptake as compared to the non-targeted liposomes in
HER2-positive breast cancers [61, 62]. Some of the other examples related to NP cancertargeting include CC52 antibody-modified liposomes against colon adenocarcinoma, antiCD19 for B-cell lymphoma, and 34A antibody for metastatic lung cancer [63, 64].
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Table 1-2: Common receptors and ligands for cancer drug targeting [17, 65, 66].
Receptors

Targeting ligands

Transferrin receptors (TfRs)-TfR1 and Transferrin
TfR2
Folate receptors

Folate

Integrin receptor

αvβ3

Epidermal growth factor receptor (EGFR): Epidermal growth factor
EGFR (ErbB1, HER1), ErbB2 (HER2),
ErbB3 (HER3) and ErbB4 (HER4)
Fibroblast growth factors (FGFRs)

Fibroblast growth factor

Sigma receptors

S1R and S2R receptors

Bombesin receptors (BnR)

The gastrin-releasing peptide (GRP) receptor;
neuromedin B receptor (NMB) and orphan
receptor (BRS-3)

Somatostatins (SSTRs) receptors

SSTR1-5

Endothelin receptors (ETRs)

ETRA and ETRB, Endothelin’s (ET-1-3).

Low-density lipoprotein (LDL) receptor

Low-density lipoprotein

Asialoglycoprotein receptor

Glycosylated polylysine

Galactose/Glucose/Mannose receptors

Galactose/Glucose/Mannose

Others

Follicle

stimulating

hormone

receptors

(FSHRs); Biotin receptors (BRs); C-type lectin
receptors

(CLRs);

Asialoglycoprotein

receptor (ASGPR); and Neuropilin 1 (NRP-1).
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However, antibodies are relatively large (~150 kDa in molecular weight), and their
conjugation often results in poor size control and reduced stealth capability (evasion by the
immune system) [67, 68]. These shortcomings led to the emergence of alternative targeting
ligands. Such ligands include variations of whole antibodies such as Fab fragments and
single-chain variable fragments, growth factors and nutrients whose receptors are overexpressed in cancer cells, RNA-based aptamers and peptides such as RGD and LyP-1 that
target tumor vasculatures [69, 70, 71]. The small physical dimension of these alternatives
enables high ligand density and more effective multivalent targeting without compromising
the particle’s circulation time.
Active targeting to receptors has some drawbacks which limit its potential clinical
usage. One of the crucial factors to be considered is the availability and the capacity of the
receptors to be targeted by the probe. It is essential since the number and the availability
of cell surface receptors determines the ability/efficiency of specific binding of the
targeting ligand. Several clinically approved actively targeted systems are listed in Table
1-3. The efficiency of the active targeting is also determined by the elimination of the drug
delivery system from the circulation and degradation of the ligand while in circulation.
Short in-vivo circulation half-life could be an advantage in imaging because it quickly
eliminates the background caused by the excess probe. However, in drug targeting, short
half-life gives the targeted delivery system less time to penetrate into the target tissue. Long
circulation times are especially important when the target is outside the vasculature [72,
73]. In summary, for both passive and active targeting of nanomedicine, short circulation
time in the blood is a major challenge. The current approaches to enhance the circulation
time of nanomedicine are discussed under section 1.4 and also in chapter II.
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Table 1-3: List of clinically approved actively targeted nanomedicines [34].
Name

Targeting moiety

Tositumomab

Mouse anti-CD20

(Antibody-

antibody

Drug
131

Iodine

Cancer
Non-Hodgkin's
lymphomas

radioactive element
conjugate)
Denileukin diftitox Interleukin 2

Diphtheria

Cutaneous

(Fusion protein of

toxin

lymphoma

targeting agent and

fragment

T-cell

therapeutic protein)
Gemtuzumab

Humanized

anti- Calicheamicin Acute

(Antibody-drug

CD33 antibody

myeloid

leukemia

conjugate)
Ibritumomab

Mouse anti-CD20

(Antibody-

antibody

radioactive element
conjugate)

90

Yttrium

B-cell non-Hodgkin’s
lymphoma

13
1.4. Enhancing the Systemic Circulation Time of Nanomedicines
Majority of chemotherapeutics are given intravenously. When delivered intravenously,
irrespective of the therapeutic objective of the NPs, their circulation time in the blood is a
key determinant for efficient accumulation in the target tissues [74, 75]. However,
majority of the existing technologies for nanomedicine suffer from two major
shortcomings in drug accumulation in cancer tissues: (i) rapid elimination from the
systemic circulation before reaching the cancer tissue (ii) poor tumor accumulation and
penetration due to inadequate vasculature and extensive extracellular matrix in the tumor
[40, 41, 74, 76]. NPs are commonly eliminated from the body via a two-step process. The
first step involves adsorption of the serum proteins of the complement system on the
surface of NPs, which is termed as opsonization. Following opsonization, the NPs are
engulfed by the circulating macrophages or the macrophages of the liver and spleen or the
reticuloendothelial system (RES) of the liver [77-79]. More specifically, hydrophobic
and/or charged NPs suffers from high opsonin mediated immune clearance [80]. It is very
critical to enhance the circulation time of nanomedicine for clinical advancement.
Currently, there are three major strategies proposed for enhancing the circulation
time of NPs: (i) modifying the physicochemical characteristics such as size and shape of
the NPs, (ii) altering the surface of the particles to reduce opsonization, and (iii)
mimicking blood cells and/or closely attaching on them to evade immune recognition.
The size of a nanocarrier is a crucial factor that determines the circulation in the blood
which in turn is related to tumor accumulation, retention and drug release. For example,
liposomes > 200 nm in diameter do not extravasate into tumors [81]. The same study
showed that PEGylated unilamellar liposomes between 5 to 150 nm have increased blood

14
circulation (half-life ~50-55 h) and thus, increased tumor accumulation and anti-tumor
efficacy. In general, smaller sized particles are less likely to be taken up by macrophages
than the larger ones. However, the smaller particles demonstrate widespread accumulation
in other organs and are also rapidly excreted through glomerular filtration. In general, the
recommended size of the NPs is larger than 20 nm to avoid glomerular filtration, but
smaller than 100 nm to minimize uptake by mononuclear phagocytic cells [82-84].
There are a variety of techniques employed for the surface modification of NPs to
prevent and/or reduce the opsonization. The surface modification could be accomplished
either by incorporating the surface modifying agent during the preparation of particles or
attaching on to the surface of prepared particles by a covalent bond or passive adsorption
[85-87]. The surface of the NPs is altered to become hydrophilic to prevent the uptake and
clearance by macrophages. Hydrophilic coating of the surface further provides protection
against plasma protein adsorption (opsonization) [78]. Polyethylene glycol (PEG) is
currently the gold standard for the stealth surface coating, and it is present in many FDAapproved products. The process of coating the surface of NPs with PEG is called
PEGylation. PEGylation enhances the surface hydrophilicity of NPs without adding a
charge to it [39, 79, 88-92]. However, concerns and limitations of PEG such as its nonbiodegradability, immunological responses, and the toxic side products that accompany
its synthesis, have motivated the search for safer and more compatible substitutes. Of the
utmost concern is the emergence of anti-PEG antibodies that have been observed in
approximately 25% of patients and normal humans, which leads to accelerated blood
clearance of the particles in subsequent injections. Such observations raise concern over
the ubiquitous use of PEG and demonstrate the need for novel, non-immunogenic
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approach in prolonging NP circulation half-life [93-99]. More details on PEGylation and
its limitations are described in detail in Chapter II. Other polymers used for stealth coating
of NPs include Polyoxazolines, Poly (amino acids) such as poly (hydroxyethyl Lglutamine) or poly (hydroxyethyl-L-asparagine), N-(2-hydroxypropyl) methacrylamide
(HPMA), Polybetaines, Polyglycerols, Polysaccharides, Poloxamers and Poloxamines
[74, 100].
Recently, several biomimetic approaches have been proposed to enhance the
systemic circulation time of NPs [75, 76, 101, 102]. For instance, blood cells (like
erythrocytes) are known to remain in the circulation for months. Red blood cells (RBCs)
have gained attention as alternatives to PEG for enhancement of the circulation time and
tumor targeting of NPs [76, 80, 103-118]. RBCs have been investigated as drug carriers
since they possess intrinsic biocompatibility and non-immunogenicity, enhanced
circulation and ability to be cleared from the circulation. RBCs express various surface
markers such as receptor/transporter proteins, glycans and acidic sialyl moieties [113].
RBC-targeted nanoparticulate delivery systems have demonstrated superior circulation
half-life and better tumor penetration than PEGylated NPs as observed in mouse models.
The most common RBC-based strategies to enhance the circulation time of NPs include
[76, 80, 103, 104, 106-111, 118, 119]: (i) preparing nanocarriers with RBC membranesThis involves coating or preparing nanocarriers using RBC membranes. This approach is
highly biocompatible, prolongs circulation time and/or tumor targeting. (ii) coating the
surface of the polymeric-NPs with RBC membrane- This approach involves camouflaging
the NPs surface with the erythrocyte exterior for long circulation while keeping the
applicability of the polymeric core and (iii) attaching the NPs on to the surface of RBCs-
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Coupling or attaching to the RBC surface represents an alternative strategy to the other
two mentioned above. This is possible since the RBC membrane provides a surface area
that could be utilized to couple proteins or therapeutics molecules [120].
RBCs express various surface markers such as receptor/transporter proteins,
glycans and acidic sialyl moieties for conjugation to NPs. In this dissertation (chapter II),
we have designed a unique strategy based on the physiological interaction between
nutritional transporters (glucose transporters-GLUT1) present on the RBCs membrane
with their natural ligands. We hypothesize that by conjugating glucose on the surface of
NPs enables them to bind to GLUT1 on the membrane of RBCs to travel along for
enhanced circulation time. Stealth coated RBC-NPs also reduce the in-vitro macrophage
uptake as seen with the solid gold nanospheres [121]. They could be employed either for
continuous release of drugs in the circulatory systems or for targeted delivery to specific
organs. Hence, developing biomimetic approaches for the enhancement of the circulation
time of NPs of considerable interest in the field of medical nanotechnology. Moreover, it
would require not one but an amalgamation of available strategies [100], such as
employing appropriate size, shape, surface and mechanical properties, exploitation of
natural cells to achieve an enhancement of circulation time for particulate delivery systems
[121-126].

1.5 Receptors versus Transporters as Targets for Active Targeting for Cancer
To qualify as a target for active targeting for cancer, the target molecule has to be
differentially expressed in cancer tissue compared to the healthy tissue. Various receptors
have been reported over the years as targets for cancer-drug targeting (Table 1-2). The
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current targeting strategies primarily focus on modifying ligands on the surface of the nanobased drug delivery system to recognize and interact with specific receptors on the surface
of the cell membrane. However, the targeting efficiency has been limited by the variability
and heterogeneity of the receptors. It has been found that different patients with the same
disease have differential expression levels of receptors and differential expression of the
same receptors at different stages of the disease for the same patient. Thus, receptor-based
targeting strategies have not been brought to clinics and there is a need to develop
alternative targeting strategies [65, 127].
Recently, transporters have become emerging targets for the development of
targeted drug delivery systems. Transporters are membrane proteins that have specificity
to a group of structurally similar ligands. The ligands, once bound, are transported into the
cell through a channel within the protein structure of the transporter. The ligands for
transporters are usually small molecules, such as glucose or amino acids, that could pass
through a small transporter channel. It would not be possible for larger molecules or NPs
to transport through the channel to enter the cell. In contrast, receptors transport the ligands
or NPs with the ligand into the cell through endocytosis. The endocytotic vesicles are large
enough to carry NPs along with the ligand. However, in the last few years transporters have
been explored to deliver drugs specifically to cancer cells as they have also been shown to
induce endocytosis. The advantages of utilizing transporters as targets for nano-based
cancer drug targeting compared to receptors could be categorized into two different aspects
(i) pathological differences and (ii) delivery related advantages. The pathological
differences include: (i) A strong positive correlation exists between the transporter
expression versus invasiveness of the cancer cells and poor prognosis in multiple cancer
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types. (ii) The expression levels of transporters are less variable than the receptors. (iii)
The variability and heterogeneity in terms of expression of transporters in patients, and
within the same patient during the various stages of diseases, are less as compared to the
receptors. The delivery advantages of transporters as compared to receptors include: (i)
Most of the targeting moieties for receptors are macromolecules, whereas in the case of
transporters they are small molecules. (ii) Lack of potential immune reactivity is a unique
advantage of ligands for transporters as opposed to receptors. (iii) The ligands for
transporters are usually stable and could be structurally modified, as opposed to those for
the receptors. [65, 127].
Nutritional transporters are a group of influx transporters that transport hydrophilic
nutrients such as sugars or amino acids across the membrane. Cancer cells are known for
their uncontrolled rapid growth and proliferation, therefore, are in high demand for
nutrients (glucose, amino acids, fatty acids, vitamins) [128]. To meet the demand for high
nutrients, cancer cells usually express high levels of nutritional transporters compared to
normal cells [129]. Similarly, cancer cells also express high levels of efflux transporters
such as P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and
breast cancer resistance protein (BCRP), which play a role in drug resistance and survival.
This would enable to either inhibit or use the endogenous over-expression of these
transporters as potential targets for the development of strategies for cancer. Since the
cancer cells induce these specific transporters to fulfill their increased demand of nutrients
and metabolic needs, it is expected that normal cells would not be expressing or their
expression would be relatively low, thus reducing undesirable side effects [65, 127, 129].
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1.6. Transporters in Drug Delivery for Cancer
Hydrophilic molecules are unable to readily diffuse across the membrane. For this, they
depend upon channels, pumps and/or transporters to move in and out of the cells and
organelles [130]. The transporter’s primary function is to regulate the influx and efflux of
various essential endogenous compounds such as nutrients, amino acids, sugars, and
inorganic ions, etc. [131]. Drugs that possess structural similarity to these substrates are
recognized and transported into the cell by transporters [132]. Transporters often work in
tandem for the regulation of the transport of compounds across the barriers throughout the
body, thus playing a crucial role in the absorption, distribution, metabolism, and excretion
(ADME) of structurally and pharmacologically diverse molecules [130]. Approximately
10% of the human genome encodes for proteins with transporter-related functions, [122]
which emphasizes their complex role in transporting molecules across the tissues.
Furthermore, there has been considerable interest in transporters as major targets for
developing new drugs [122].

1.6.1. Classification of Transporters
Transporters could be classified into broadly four ways: (i) efflux vs influx transporters
(ii) secretory vs absorptive transporters (iii) ATP binding cassette transporters (ABCs) vs
solute carrier (SLCs) transporters and (iv) Passive vs active transporter [133]. Efflux
transporter pumps the substrates out of the cells while the influx transporters are
responsible for the uptake of substrates into the cells. Transporters that transfer their
substrates into the systemic circulation are absorptive and those that excrete substances
from blood circulation are secretory transporters. Membrane transporters can be further
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classified as ABC transporters and SLC transporters. The ABC transporters are primary
active transporters, that efflux out wide range of substrates. The SLC family includes
transporters that function by secondary active transport and facilitative diffusion. They are
located on the cell membrane as well as on the intracellular membrane of organelles. Active
transporters utilize adenosine triphosphate (ATP) to pump the molecules against the
concentration gradient. They are further classified as primary or secondary active
transporters according to the mechanism of energy coupling. Passive transport is the
movement of molecules down the concentration gradient without the need for energy [132]
[134].

1.6.2. Membrane Transporters
Membrane transporters are integral membrane proteins that facilitate the transport of drugs
or macromolecules via the processes of facilitated diffusion or active transport [95]. They
exist within and span the membrane across which they transport exogenous and
endogenous substances including major nutrient metabolites [95, 135]. Identification of
various genes has made it possible to classify the transporters into two distinct
superfamilies’, namely: ATP binding cassette proteins (ABC) transporters and solute
carrier proteins (SLC) transporters [135].
1.6.2.1. ABC Transporters
ABC transporters are ATP binding cassette proteins. They are the largest superfamily of
transport proteins found in humans. They utilize energy from hydrolysis of ATP to carry
out the function of translocation of various substrates across the membranes [132]. There
are 40 ABC transporters classified into 7 subfamilies based on their amino acid sequence
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identity from A to G subfamily as: ABCA, ABCB, ABCC, ABCD, ABCE, ABCF and ABCG
[95, 135, 136]. Numerous clinical studies have revelated that multi-drug resistance
phenotype in tumors is associated with over-expression of P-gp, MRP1, MRP2, MRP3,
MRP4, MRP5 and BCRP, which primarily mediate the efflux of xenobiotics and drugs.
Therefore, to develop an effective chemotherapeutic regimen, thorough knowledge about
the mechanisms of multi-drug resistance caused by ABC transporters is required [135,
136].

1.6.2.2. SLC Transporters
SLC transporters comprise both the facilitated and secondary active transporters. They
utilize electrochemical gradient for facilitating the movement of substrates across the
membranes or ion-gradients generated by the ATP-dependent pumps to transport substrate
across the concentration gradient [130]. The SLC transporters either work by passive
diffusion along the concentration gradient of the substrate or by co-transport against the
concentration gradient of another solute. These transporters do not possess ATP-binding
sites. They constitute the largest family of membrane transporter proteins in the human
genome with approximately 400 SLC transporter genes that have been identified and
grouped into 55 families [133]. The SLC transporters function as influx transporters for
nutrients and other essential substances for cell survival [95, 137].

1.7. Nutritional Transporters as Targets for Cancer-targeted Drug Delivery
One of the hallmarks of cancer cells has been uncontrolled growth and proliferation, which
increases the demand of nutrients that are required for the synthesis of DNA, RNA and/or
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as a source of metabolic energy [129]. The nutrient demand is fulfilled by glucose, amino
acids, vitamins, and fatty acids, etc. Most of these nutrients are hydrophilic in nature and
cannot permeate across the plasma membrane in mammalian cells. The uptake of these
hydrophilic nutrient molecules occurs through nutritional transporters that are located on
the plasma membrane. Such a high demand for nutrients for their rapid growth coupled
with poor availability of nutrients due to inefficient development of tumor vasculature
propel cancer cells to highly express nutritional transporters for their survival [138].
Therefore, it is imperative to understand the changes in the function and expression of
nutritional transporters in cancer cells as compared to the normal cells. Identification of
specific nutrient transporters upregulated in cancer cells as compared to normal cells would
enable to either inhibit the cellular signaling pathways that are responsible for their
induction to specifically block the function of that transporter to impair the growth of the
tumor. Nutritional transporters have become targets for new anti-cancer drug discovery
[65, 129, 133].
Numerous nutrient transporters are implicated in cell growth, of which the glucose
transporters, amino acid transporters (includes both amino acid exchangers and amino
acid importers) and the monocarboxylate transporters have been extensively studied for
their association with cancer (Table 1-4) [138]. The increased demand for glucose by the
cancer cells is regulated via the induction of GLUT1 and SLGT1 transporters. This
increased entry of glucose is well-coordinated with increased glycolysis, which leads to
higher lactate production. Cancer cells upregulate MCT4 transporters to expel lactate out
of the cells. Similarly, the increased demand for amino acids is meet by cancer cells by
induction of LAT1, ASCT2, xCT/4F2hc, and ATB0,+. Evidence exists on the

23
pharmacological inhibition of these transporters to control the cancer cell growth. Hence,
these transporters possess the ability as targets for cancer therapy [129, 138].
Recently, nutritional transporters have been explored as alternatives to deliver
drugs, diagnostic markers or nano-drug delivery systems across cancer cells for active drug
targeting (Table 1-7 and 1-8) [65, 129, 133]. Examples of this include, tumor-specific
delivery of positron emission tomography (PET) imaging agent, 2-[fluorine-18]-fluoro-2deoxy-D-glucose (FDG) that utilizes glucose transporter activity that arises due to the
enhanced requirement of glucose and other sugars by the cancer cells [139].
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Iodine

therapy has been utilized in patients with thyroid cancers due to the ability of the thyroid
to accumulate iodine [140].

1.7.1. Glucose Transporter Family and their Role in Cancer
Glucose is one of the essential metabolic substrates which cannot diffuse across the lipid
bilayer due to its hydrophilicity [122]. The transport of glucose into the cytosol is mediated
by two families of hexose transporters: the sodium-dependent glucose transporters
(SGLTs) delivers glucose against the concentration gradient utilizing the sodiumelectrochemical gradient, whereas the GLUT family of transporters translocates glucose
along the concentration gradient using a facilitative diffusion. The GLUT proteins belong
to the solute carrier 2A family SLC2A (SLC2A1–SLC2A14). To date, 14 forms of GLUTs
have been sequenced in humans, which have been categorized into three distinct classes
based on the sequence similarity: class 1 (GLUTs 1-4 and 14), class 2 (GLUTs 5, 7, 9 and
11) and class 3 (GLUTs 6, 8, 10, 12 and HMIT) (Table 1-5) [122, 141]. As a member of
the major facilitator superfamily (MFS) of the membrane transporters, GLUTs possess
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some common structural similarities such as presence of ~500 amino acids, 12transmembrane helices, an N-linked glycosylation site, and intracellular -NH2 and –COOH
terminus including several conserved residues and motifs [129, 133] [141].

Table 1-4: Nutrient transporters implicated in cancer [65, 129].
Common Name

SLC Designation

Tissues Over-expressing Transporter

Glucose Transporters
Brain, breast, pancreatic, lung, prostate,
GLUT1

SLC2A1

head and neck, gastric, colorectal, renal,
thyroid, and hepatocellular
Breast, ovarian, lung, stomach, oral

GLUT3

SLC2A3
squamous cell, bladder
Lung, gastric, thyroid, multiple

GLUT4

SLC2A4
myeloma

GLUT12

SLC2A12

Prostate and breast

SGLT1

SLC5A1

Prostate, lung pancreatic, head and neck
Amino Acid Exchangers

ASCT2

SLC1A5

Glioma, hepatoma

xCT/4F2hc

SLC7A11/SLC3A2

Brain,

pancreatic,

hepatocellular,

leukemia
LAT1/4F2hc

SLC7A5/SLC3A2

Prostate, brain, colon, liver, lung, and
skin
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LAT3

SLC43A1

Prostate

CAT-1

SLC7A1

Glioma

Net Amino Acid Importers
SNAT 1-5

SLC38 A1-A5

ATB0,+

SLC6A14

EAAT2

SLC1A2

PAT1/LYAAT-1 SLC36A1

Colorectal, cervical, breast
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Table 1-5: Classification of GLUTs with respective details about the transporters.

Transporter

Gene

Predominant

Tissue and Cellular
Role and Properties

[142]

Name

Substrates

Expression

SGLT Transporters
SGLT1

SLC5A1

Glucose, galactose

The small intestine,

Intestinal and renal absorption of

salivary gland, heart,

glucose.

and kidney.
SGLT2

SLC5A1

Methyl-α-D-

Kidney.

glucopyranoside

Renal absorption of glucose from
the glomerular filtrate.

Class I GLUT Transporters
GLUT1

SLC2A1

Glucosamine,

Brain, erythrocytes,

Basal level glucose uptake.

glucose, galactose and blood-brain barrier,

GLUT2

SLC2A2

mannose.

fetal tissues.

Glucosamine,

Liver, kidney, brain,

It is a high capacity and low-

glucose, galactose,

pancreatic islet cells

affinity glucose transporter,

fructose and mannose. and intestine.

trans-epithelial glucose and
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fructose transport. Glucose
sensing in the pancreatic β-cells.
GLUT3

GLUT4

GLUT14

SLC2A3

SLC2A4

Glucose, galactose,

Neurons of brain and

mannose, and xylose.

testis.

Glucose and

Skeletal and cardiac

It is expressed in tissues which

glucosamine

muscle, adipose

have insulin-stimulated acute

tissues.

glucose transport.

Testis

--

SLC2A14 --

Neuronal glucose transporter.

Class II GLUT Transporters
GLUT5

SLC2A5

Fructose

Kidney, testis,

Fructose transporter.

muscle and small
intestine.
GLUT7

SLC2A7

Glucose and fructose

The small intestine,
colon, prostate, and
testis.

--
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GLUT9

SLC2A9

Glucose and fructose

Kidney, liver, small

--

intestine, placenta,
lung, and leucocytes.
GLUT11

SLC2A11 Glucose and fructose

Heart and muscle.

Possess three different isoform
GLUT11a, GLUT11b, GLUT11c
with distinct tissue distribution.

Class III GLUT Transporters
GLUT6

SLC2A6

Glucose

Spleen, brain and

--

leucocytes
GLUT8

SLC2A8

Glucose, fructose, and Brain, testis, adrenal
galactose

GLUT10

--

gland, liver, spleen.

SLC2A10 Glucose and galactose Heart, brain, liver,
placenta, lung,
kidney, pancreas.

It is associated with causation of
arterial tortuosity syndrome.
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GLUT12

GLUT13

SLC2A12 Glucose

SLC2A13 Myo-inositol

Prostate, placenta,

Similar to GLUT4, it is

adipose tissue heart,

transported to the plasma

skeletal muscle.

membrane in response to insulin.

Brain and adipose

--

tissue
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1.7.1.1. GLUT1 Transporter
GLUT1 is the most ubiquitous and extensively studied glucose transporter. Its properties
have been extensively studied in human RBCs. GLUT1 corresponds to 10% of the total
integral membrane protein in RBCs [143]. Through this, glucose equilibrates between the
serum and red cell cytoplasm. It is primarily present in the plasma membrane. Substrates
of GLUT1 are glucose, mannose, galactose, glucosamine, etc. It has multiple substrates but
possesses a high affinity for glucose (Table 1-5). The structural requirement for binding of
2-amino-2-deoxy glucose to GLUT1 transporters requires the presence of free hydroxyl
groups at the carbon 1, 4 and 6 in the 2-amino-2-deoxy glucose molecule. The amino group
at the carbon 2 of glucose is most suitable for recognition and binding to GLUT1
transporter on the RBCs membrane (Figure 1-2). It is actively inhibited by cytochalasin B
and phloretin. It also plays a critical role in cerebral glucose uptake since it is highly
expressed on the brain endothelial cells (Table 1-5) [129, 141].

Figure 1-2: Glucose binding to GLUT1 transporter. Modified and adopted from [141].
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GLUT1 is highly expressed in the majority of cancer types. This could be due to
the aggressive nature of cancers, which demonstrates an increased demand for metabolic
energy, especially through glycolysis using glucose. Switching the metabolic pathway
from mitochondrial oxidative phosphorylation to aerobic glycolysis under hypoxic
conditions is a hallmark of the cancer cells. This switch of the metabolic pathways is an
energetically efficient process that requires excessive amounts of glucose [143, 144]. This
phenomenon is termed the Warburg effect. This increased dependence of glucose gives rise
to enhanced expression and surface transport of GLUTs more specifically GLUT1 [145].
The factors that are responsible for the up-regulation of GLUT1 include hypoxia-inducible
factor-1 (HIF-1), c-MYC, AKT, Ras and p53, etc. Oncogenesis also plays a critical role in
the induction of GLUT1 [11, 144].

1.7.1.2. GLUT1 Expression in Various Cancers
GLUT1 is a key rate-limiting factor in the transport and metabolism of glucose in cancer
cells. GLUT1 is overexpressed in a number of cancer types including breast, brain, ovarian,
hepatic, pancreatic, esophageal, renal, lung, cutaneous, colorectal, endometrial, bladder,
cervical, hepatocellular, head and neck and gastric cancers [146-149] (Table 1-6). This
overexpression of GLUT1 in various cancers is utilized for tumor diagnosis, imaging,
therapy, and disease management. An increased level of expression is observed in cancers
of high grade and high proliferative index. The survival of cancer patients is related
reciprocally to the expression level of GLUT1 [65, 150]. GLUT1 is expressed in 42% of
breast tumors with increased expression in cancers of higher grade and proliferative
activity as compared to non-cancerous tissues. Subsequent studies also reported ~47% and
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51% expression levels of GLUT1 in breast cancer [151]. Godoy et al. have reported as high
as 91% positive staining of the invasive ductal carcinoma analysis as compared to control
[152, 153, 154, 155, 156]. This clearly indicates the consistency of GLUT1 overexpression
in ductal carcinoma [155, 157].
In addition, the levels of GLUT1 protein expression correlates to poor prognosis in
a wide range of solid tumors [158, 159]. For example, high levels of GLUT1 in breast
cancer correlates with poor survival, aggressive biological behavior and more malignant
potential in patients. GLUT1 expression is associated with increased malignant potential,
poor prognosis and invasiveness in the lung, colorectal, gastric and ovarian cancers [160
161, 162]. A thorough systematic review and meta-analysis of a total of 26 studies
including 2948 patients revealed that overexpression of GLUT1 correlated with poor 3year overall survival and 5-year overall survival of tumors [150]. Haber et al. through their
studies have shown that the risk of dying from colon cancer was 2.3 times higher in patients
with high GLUT1 expression, as compared with low expression and correlated to poor
prognosis [163]. Reis et al. utilized a scoring system and demonstrated that GLUT1 is
correlated with increasing malignant potential in non-invasive and invasive urothelial
carcinomas of the bladder [164]. Chen et al. report that Sirtuin 1 increases the transcription
activity and expression of GLUT1, therefore, promoting the cell proliferation and
glycolysis in bladder cancer cells. Nemejcove et al. study confirm high expression of
GLUT1 in endometrioid carcinomas. Among 184 cases studied, 160 (87%) cases
demonstrated increased expression of GLUT1 [165]. The combined studies of Younes et
al., Yamamoto et al., Noguchi et al. report increased expression of GLUT1 in the stomach
and esophageal cancer and its relation to progression in Barrett’s metaplasia [166, 167,
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168]. These studies suggest that GLUT1 is a prognostic indicator and a potential
therapeutic target in tumors [145]. Similar increased GLUT1 expression patterns have been
found in thyroid, lung, ovarian, and cutaneous cancers as shown in Table 1-6 [158, 169].

Table 1-6: GLUT1 expression in various cancers.

Cancer Type

Hepatocellular
(HCC)

Results/ Expression Patterns

Reference

carcinoma The results of mRNA and protein expression [170]
in 152 patients revealed that ~68.2% of
human HCC tissues demonstrated higher
GLUT1
noncancer

expression
tissue.

as

compared

Increased

to

GLUT1

expression affected the proliferation and
invasiveness, promoting tumorigenesis of
HCC.
Gastric cancer

GLUT1 is upregulated in gastric cancer and [171]
is related to unfavorable clinical survival and
first progression survival

Prostate cancer

The results reveal that GLUT1 expression is [172]
considerably higher in prostate cancer tissues
than the normal tissues as well as positively
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correlates with the prostate-specific antigen
(PSA) level and Gleason score.
Head and neck squamous Through immunohistochemical analysis on
cell carcinoma

135 human samples of cancer, author report
significantly higher (~96% cases) expression
of GLUT1 in neoplastic vs non-neoplastic
samples.

GLUT1

is

expressed

in

basal/parabasal epithelial cells and in oral
carcinoma
Cervical cancer

Mendez et. al. through histologic analysis in [173]
31 patients’ samples report expression of
GLUT1. The results reveal that GLUT1 was
positive in all 31 cases and was related to the
grade of the tumor.

Pancreatic cancer

Reske et al. showed that overexpression of [174]
GLUT1 to increased FDG uptake in
pancreatic carcinoma.
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Table 1-7: List of transporters and their substrates for cancer targeting [65].
Transporter

Gene

Ligands/Substrates

SMVT [175]

SLC5A6

Biotin

ASBT [176, 177]

SLC10A2

Deoxycholic

acid,

TetraDOCA

and

Taurocholic acid
OCTN2 [178]

SLC22A5

L-carnitine

GLUT1

SLC2A1

2-Deoxy-D-glucose

and

glucose
GLUT4

SLC2A4

Glucose

ATB0,+

SLC6A14

Lysine, Aspartate

LAT1

SLC7A5

Glutamate, phenylalanine

MCT1

SLC16A1

β-hydroxybutyrate
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Table 1-8: Active targeting strategies employing substrates of transporters. Modified and
adopted from [65].
Transporter

Gene

GLUT1

SLC2A1

Substrate

Nanomedicine

Drug
NA

Purpose

2-Deoxy-D-

DMSA-DG-

For increased site-

glucose and

NPs and

specific absorption at

glucose

nanoparticles

the tumor site and
brain

GLUT4

SLC2A4

Glucose

Quantum dots

NA

Increasing
absorption in muscle

LAT1

SLC7A5

Glutamate

MCT1

SLC16A1 β-

Nanoparticles

Paclitaxel

Solid-lipid

Docetaxel Increase site-specific

hydroxybutyrate nanoparticles
GLUT1

SLC2A1

2-Deoxy-D-

Nanoparticles

Breast cancer

absorption in brain
Paclitaxel

glucose

To enhance bloodbrain barrier
permeation and

LAT1
OCTN2
ASBT

D-Glucosamine

Nanoparticles

Paclitaxel

Glutamate

Liposomes

Docetaxel targeting

SLC22A5 L-carnitine

Nanoparticles

Paclitaxel

For enhanced oral

SLC10A2 Deoxycholic

Conjugates

Insulin

absorption

and micelles

and

SLC7A5

acid and
Taurocholic
acid
*NA- Not applicable

Docetaxel

increased glioma
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1.7.2. Strategies to Target GLUT1 in Cancer
Current research efforts are focused on developing novel drug delivery systems that
structurally resemble the endogenous substrates (glucose and amino acids) and thereby
enable them to reach the target sites, minimizing the amount reaching the non-target
tissues. For this purpose, a major approach, known as carrier-mediated transport, is utilized
to target and make use of endogenously expressed transport substrates for the development
of drug delivery systems. The most recent strategies include nanoscale drug delivery
systems, prodrug design and conjugating of drugs with the nutrients (glucose, amino acids),
etc. In brief, the strategies involve: (i) modification of an existing drug or polymer to give
a ‘pseudo nutrient’ structure that could be recognized and transported by the endogenous
transporter (ii) conjugation of drug or polymer with a nutrient that is able to be transported
by the endogenous transporter (Figure 1-3). Various endogenous ligands for transporters
are available for cancer drug targeting (Table 1-7). By using these ligands on the surface
of a nanoparticulate vehicle, chemotherapeutic agents have been targeted to various cancer
tissues (Table 1-8) [65], [144, 179-182].
Of all the nutritional transporters, GLUT1 has been extensively studied for cancer
targeting due to its consistent over-expression in cancer patients (Section 1.7.1.2 and Table
1-6). The Table 1-9 below provides a collection of strategies that target high levels of
GLUT1 in cancers for therapeutic purposes: to inhibit the function of GLUT1 or to deliver
drugs using a prodrug strategy (Table 1-9) [180, 183, 184].
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GLUT1-mediated transport
Altering transport of anticancer
drugs as GLUT1 substrates

GLUT1 inhibitors
Small molecule drugs and their
combinations

Pro-drug development
Conjugation of existing
anti-cancer drugs with
glucose or its derivatives

Cancer biomarker
Prognostic marker for disease
identification, staging &
localization

GLUT1 -Target
for cancer targeted
drug delivery

Nanotechnology
Developing liposomes,
nanoparticles, micelles, dendrimers
using polymers or delivery systems
modified with substrates of GLUT1
transporter

Tumor imaging
• Diagnosis, staging and localization
• Glucose containing PET tracer

Figure 1-3: Potential Strategies to Target GLUT1 Transporters.

Table 1-9: Comprehensive list of various strategies using GLUT1 transporter in cancer.
Strategy and
Polymer
Drug

Therapeutic

Major conclusions

employed
application
Cisplatin
[161]

NA

Novel platinum-

Patra et al. in their work have

glucose drug

synthesized three novel glucose-

conjugates

platinum conjugates (Glc-Pts 1-3).
The conjugate (Glc-Pt 1)
demonstrated preferential
accumulation in cancer cells as
opposed to the normal cells by
utilization of the glucose and
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organic cation transporters that
are overexpressed in cancers.
Oxaliplatin

NA

[182]

Selective tumor

Liu et al. have reported fluorine

targeting with

substituted series of glucose,

fluorine-

mannose, and galactose-

containing

conjugated (trans-R, R-

platinum (II)

cyclohexane-1, 2-diamine)-2-

glycoconjugates

flouromalonato-platinum (II)
complexes for their selective
tumor targeting via the GLUT1
transporter. The conjugates
demonstrate high aqueous
solubility, improved cytotoxicity
and enhanced cellular uptake on
GLUT1 overexpressing cells. The
glucose conjugated compound
(5a) demonstrates enhanced invivo efficacy in an HT29
xenograft model and leukemiabearing DBA/2 mice model as
compared to oxaliplatin.

Oxaliplatin
[185]

NA

Platinum

The author reports two mannose

complexes

conjugated platinum complexes.
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conjugated to

Both these compounds show

mannose for

enhancement in water solubility

effective tumor

and enhanced cytotoxicity in six

targeting by

different human cancer cell lines.

GLUT1

In-vivo these compounds

transporter

demonstrate efficacy and safety
than oxaliplatin.

NA [179]

Glucose coated

Glucose-coated

iron oxide NPs

superparamagnetic internalized in tumor cell lines
iron oxide NPs via

The NPs were effectively

overexpressing GLUT1.

GLUT1
transporter in
pancreatic
adenocarcinoma
cells
NA [181]

P-aminophenyl-

Modified

The mannose modified liposomes

α-D-

liposomes of

demonstrated higher cellular

mannopyranoside mannopyranoside
within mice brain.

uptake in GLUT1 overexpressing
cell lines. Transcytosis by GLUT1
and GLUT3 was responsible for
the uptake of mannose modified
liposomes into the brain.
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NA [186]

γ-Fe2O3 NPs

Targeting GLUT1

A novel 2-deoxy glucose-based

coated with

overexpressing

contrast agent for magnetic

DMSA, modified

MDA-MB-231

resonance molecular imaging was

with 2-DG

cells with 2-DG

developed. This agent

modified SPIOs.

demonstrated enhanced cellular
uptake of SPIOs in GLUT1
overexpressing cells. This study
reports the potential of SPIOs as
promising candidates for tumor
detection probe with potential use
in MR imaging.

Doxorubicin mPEG-pLys-

GLUT1 targeted

Guo et al. through their results

[187]

nano-micelles for

show the development of nano-

hepatocellular

micelles targeted towards

carcinoma cellular

GLUT1. Cellular and in-vivo

therapy

imaging studies demonstrate

pPhe

targeting property of micelles for
hepatocarcinoma cancer. The
micelles were found to show
enhanced efficacy both in-vitro
and in-vivo.
*NA- not applicable.
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1.8. Scope and Objectives
Recent advancements in nanotechnology have unfolded novel opportunities in
medicine, especially in targeted therapeutics and medical imaging. However, the majority
of the existing technologies for nanotechnology suffer from two major shortcomings in
drug accumulation in cancer tissues: (i) rapid elimination from the systemic circulation
before reaching the cancer tissue. (ii) poor tumor accumulation and penetration due to
inadequate vasculature and extensive extracellular matrix in the tumor.
Delivering NPs through a systemic route poses a major challenge due to the
recognition of the circulating NPs by the reticuloendothelial system (RES). The
conventional approach to improve the circulation of nanocarriers has been surface
modification either by coating or conjugating with polyethylene-glycol (PEG)
(PEGylation). However, recent studies point toward an anomalous behavior of PEGylated
nanocarriers such as the ABC phenomenon, where they are cleared much faster than
expected. One reason might be that repeated injections of PEGylated nanocarriers result
in the generation of anti-PEG IgM antibodies.
Recently, transporters have become emerging targets for the development of
targeted-drug delivery systems. Nutritional transporters are a group of influx transporters
that transport hydrophilic nutrients such as sugars or amino acids across the membrane.
SLC transporters have been explored as alternatives to deliver drugs, diagnostic markers
or nano-drug delivery systems across cancer cells for active drug targeting. GLUT1 is the
most ubiquitous and extensively studied glucose transporter. Its properties have been
extensively studied in RBCs. GLUT1 is highly expressed in the majority of cancer types.
Current research efforts are focused on developing novel drug delivery systems that
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structurally resemble the endogenous substrates (glucose and amino acids) and thereby
enable them to reach the target sites, minimizing the amount reaching the non-target
tissues. The overall goal is to demonstrate the feasibility of employing nutritional
transporters (GLUT1) as novel approaches for cancer-targeted drug delivery.

To achieve this goal, the following were the specific aims of this dissertation:
Objective 1: Nano-Bio interactions to enhance the systemic circulation time,
pharmacokinetics and tumor accumulation of nanomedicine in cancer by conjugating
glucose on their surface (GLU-NPs) to ride on the RBCs through NPs-glucose interaction
with glucose transporter-1 (GLUT1) that are abundantly expressed on the membrane of
RBCs (chapter II).

Objective 2: Demonstrate the utility/feasibility of nutritional transporters (GLUT1) as an
approach for cancer-targeted drug delivery (chapter III).
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CHAPTER II

NANO-BIO INTERACTIONS TO ENHANCE THE SYSTEMIC CIRCULATION
TIME AND TUMOR ACCUMULATION OF NANOMEDICINE IN CANCER
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2.1. Introduction
Recent advancements in nanotechnology have unfolded novel opportunities in medicine,
especially in targeted therapeutics and medical imaging [3, 4, 14, 188-190].
Nanotechnology-based delivery systems such as liposomes, micelles, nanoparticles,
dendrimers, etc. have been studied extensively over the past decade for the delivery of
drugs and/or imaging agents [3, 4, 14, 77, 188-192]. Nanomedicine holds several
advantages over their free drug counterparts such as the sustained release of the
encapsulated drug, protection from degradation in circulation, and active or passive
targeting to target tissues like brain, lungs or cancer [79, 103, 112, 188, 193, 194]. Most of
the nanomedicine work has been targeted towards cancer therapy. A critical need for
reducing the toxicity of anti-cancer drugs along with the unique anatomical and
physiological differences of cancer tissues have contributed to major developments in
nanomedicine for targeted-drug delivery [14, 188, 190, 191]. However, still the delivery of
nanoparticles (NPs) by the parenteral route, especially through intravenous administration,
poses a major challenge mainly due to their recognition by the immune system as foreign
particles, which leads to their rapid clearance from the circulation. Circulating NPs are
mainly recognized by the reticuloendothelial system (RES) or mononuclear phagocyte
system (MPS) following opsonization and are rapidly removed from the circulation [78,
112, 195]. The rate of clearance from circulation is determined by various properties of the
particles such as size, surface chemistry, shape and charge of the NPs on their surface [82,
196-198]. Particles greater than 200 nm can be trapped in the fenestrations of other organs
such as spleen [199, 200], whereas particles less than 50 nm are cleared through glomerular
filtration in the kidney [82, 201]. Many particles are cleared within a matter of minutes
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from the circulation before even reaching the target site, as a result, their applicability is
heavily dependent upon their ability to remain in the circulation for a reasonable period of
time [90, 91, 197, 202].
Existing state-of-the-art technology to prolong the circulation of the NPs utilizes
surface modification of the particles by chemical or physical attachment of hydrophilic
polymers or proteins [77-79]. The surface modification provides a repulsive and/or steric
barrier, mainly to decrease the adsorption of biological components, thereby decreasing the
opsonization and clearance [78]. The polymer of choice for such applications has been
polyethylene glycol (PEG). Coating NPs with PEG (a process called PEGylation), results
in increasing the circulation time of various nanocarriers including polymeric/inorganic
NPs, liposomes, micelles and macromolecules [85, 89, 90, 199, 203]. However, recent
studies point toward an anomalous behavior of PEGylated nanocarriers. Repeated
administration of PEGylated nanocarriers to animals (mice [91, 99], rats [94, 99], beagles
[99] and rhesus monkey [97]) resulted in an unexpected “Accelerated Blood Clearance”
(ABC). ABC is a phenomenon where the clearance rates of the carriers from the
bloodstream are raised upon repeated injections [91, 94, 97]. Furthermore, PEGylation may
potentially interfere with the interaction of the nanocarriers to the target cells thereby
reducing the efficiency of the therapy [93]. Moreover, toxicological studies have shown
that PEG could lead to an increased tendency to cause blood clotting and clumping of cells
[93, 203]. Thus, there is a strong need for an innovative, yet simple strategy applicable to
a wide array of nanocarriers to enhance the nanocarriers’ circulation time to replace the
current state-of-the-art technology [86, 105, 112].
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The solution to this problem is sought in nature. Several mammalian pathogens
such as Mycoplasma haemofelis and Mycoplasma suis have been known to remain in the
circulation for up to several weeks by attaching themselves to the red blood cells (RBCs)
[204-206]. These pathogens, varying in diameter from 200 nm to 2000 nm, attach
themselves to the outer membranes of RBCs, evade recognition by the RES system, and
remain in circulation for prolonged periods of time. Recently, we and others in the field
have utilized a similar strategy to enhance the circulation time of polymeric nanocarriers
by enabling them to bind to the surface of RBCs and travel along with RBCs in the
circulation, an approach known as RBC-hitchhiking [76, 80, 103-111, 114-116, 118, 207].
RBCs represent the most abundant cellular constituent of the blood (> 99%) with
approximately 5 million RBCs found in one microliter of human blood. They have a long
circulation time (~120 ± 20 days). The RBCs possess a highly flexible structure which
allows them to pass through narrow capillary fenestrations without being leaked into
various organs and tissues [110, 113]. Furthermore, RBCs possess abundant surfacemarkers such as glycan’s, sialic acid derivatives and proteins on their membrane which
play a critical role in suppressing immune activation/recognition [76]. The above
characteristics of RBCs along with their high biocompatibility makes them an attractive
target for carrying NPs for increased circulation time [116]. For a successful translation of
RBC-hitchhiking strategy for enhancing circulation time, ideally, the interaction between
the NPs and RBC-surface molecules should happen in-situ and the interaction should be
reversible to allow the particles to escape the vasculature and reach the target site [80, 103,
107-109, 111, 113, 115, 118].
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To address the above-mentioned goals, we have designed a unique strategy based
on the physiological interaction between the nutritional transporters (glucose transportersGLUT1) present on the RBCs membrane with their ligands [208]. The glucose transporter1 (GLUT1) is abundantly expressed on the RBCs membrane. GLUT1 corresponds to ~10%
of the total integral membrane protein [209, 210]. We hypothesize that by conjugating
glucose on the surface of NPs enables them to bind to GLUT1 on the surface of RBCs to
travel along for enhanced circulation time [208, 211]. Since the particles used are larger
than the pore size of the GLUT1, the particles will not be transported into the cells but will
be attached on the surface.
In this proof-of-concept study, we demonstrate that NPs conjugated with glucose
(GLU-NPs) are capable of binding to human RBCs, in-vitro even in the presence of plasma,
and to mouse RBCs in-situ after intravenous administration. Glucose conjugation
significantly enhanced the blood circulation time of NPs compared to PEGylated NPs and
bound to RBCs in-vivo. In addition, the interaction is reversed with a magnitude of shear
that is usually experienced by RBCs in the blood capillaries. This unique in-situ strategy
has tremendous applications, especially in targeted drug delivery to leaky vasculature of
cancer tissues. Indeed, GLU-NPs were highly targeted to mouse breast tumors (4T1) that
overexpresses the GLUT1 transporter. In addition, the concept is also applicable for tumor
imaging, sustained drug delivery, and targeting to other organs such as liver or lungs, etc.
Furthermore, this versatile approach is applicable for a wide spectrum of the nano-delivery
system including liposomes, dendrimers, and micelles [208].
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2.2. Materials
2.2.1 Reagents and Chemicals
Fluorescent polystyrene particles (Ex/Em 580/605) with surface carboxyl groups (100, 200
and 500 nm) were purchased from Life Technologies Inc. (Portland, OR, USA).
Tetrahydrofuran, hydroxylamine (HA), 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide
(EDC), 2-amino-2-deoxy-D-glucose (GLU), genistein, human and mouse plasma were
purchased from Sigma Aldrich (St. Louis, MO, USA). 3H-labeled oleic and palmitic acids
were purchased from Moravek, Inc. (Brea, CA, USA). Regional Blood Bank, (Sioux Falls,
SD, USA) provided the human RBCs. GLUT1 rabbit monoclonal antibody (12939S) was
obtained from Cell Signaling Technology (Danvers, MA, USA). The DiRC18 (D12731)
dye, snakeskin dialysis membrane (10 kDa cutoff), MES hydrate and polyethylene glycol
of M. Wt. 2000 (PEG2000) and all other biochemical reagents, cell culture media, solvents,
and supplies were purchased from Fisher Scientific (Pittsburgh, PA, USA).

2.2.2 Cell Lines and Cell Culture
Mouse (4T1) origin breast cancer cells were purchased from the American Type Culture
Collection (ATCC) (Manassas, VA, USA). The 4T1 cells were cultured in Roswell Park
Memorial Institute (RPMI-1640) medium in a humidified atmosphere of 5% CO2 at 37ºC.
The medium was supplemented with penicillin/streptomycin and 10% fetal bovine serum
(FBS).
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2.2.3 Animals
BALB/cJ mice (6-weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME,
USA) or Charles River Laboratories (Wilmington, MA, USA). All animal experimentation
was performed in compliance with the regulations of the Institutional Animal Care and Use
Committee (IACUC) of the South Dakota State University, Brookings, SD, USA.

2.3. Methods
2.3.1 Surface Modification of NPs
The polystyrene NPs with carboxyl surface groups were conjugated with GLU, HA, and
PEG2000 by using EDC-chemistry [212, 213]. The NPs conjugated to GLU, HA or PEG2000
are denoted as GLU-NPs, HA-NPs, and PEG-NPs hereafter. Unless specified, GLU-NPs
stands for NPs with around 200 nm in diameter (GLU-NPs-200 nm). The GLU-NPs-100
and GLU-NPs-500 indicate glucose conjugated NPs with a diameter of around 100 nm and
500 nm, respectively. Briefly, 50 µl of polystyrene NPs from a 2% w/v suspension was
washed with 50 mM MES buffer (pH 6.0) three times and resuspended in 400 µl of the
MES buffer. The carboxylic groups were activated by adding EDC (7.5 mg) in the above
suspension and incubating for 10 min at room temperature. Subsequently, 25 mg of
GLU/HA/PEG2000 in MES buffer was added to the suspension and the reaction was carried
out for 4 h at room temperature covered in dark. After 4 h, the NPs were collected by
centrifugation at 20,000g for 30 min and washed thrice with 50 mM phosphate-buffered
saline, pH 7.0 (PBS). The NPs were stored at 4°C in presence of 20 mM sodium azide and
0.001 % Triton X-100 until further analysis.
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2.3.2 Characterization of Particles: Size and Surface Charge
2.3.2.1 Dynamic Light Scattering (DLS): The average size, polydispersity index and
surface charge (-potential) of NPs were determined using the DLS technique. Initially, the
NPs were dispersed in phosphate buffer (pH 7.4) 10 mM, sonicated using bath sonicator
and then further diluted (1:10) using filter-sterilized deionized water before recording
particle size and -potential using Malvern Zeta-Sizer, Malvern Ltd, MA, USA [214-217].

2.3.3 Scanning Electron Microscopy
A FEI XL40 SEM at 3-5 kV with a 5 mm working distance was used for imaging both the
cells and the surface conjugated NPs. The cells and the NPs attached to RBCs were imaged
in a dehydrated state and prepared using a standard cell surface fixation technique. The
samples were incubated with a 2.5% glutaraldehyde solution for the cross-linking of
surface proteins. Images were acquired after 2 min of palladium coating via a Hummer
sputtering system [103].

2.3.4. In-vitro Binding of NPs to RBCs
The in-vitro binding of GLU, HA, PEG2000 conjugated NPs with human RBCs was
determined by incubating an increasing number of NPs with 1 × 105 RBCs in sterile PBS
for 4 h at 37°C at 100 RPM. The RBCs were separated from unbound NPs by centrifugation
at 800g for 10 min and washing three times with sterile PBS. The number of NPs bound to
RBCs was determined by measuring fluorescence at Ex/Em 580/605 nm using fluorimeter
(Molecular Devices SpectraMax Plus Microplate Reader). Precautions were taken to
minimize light exposure to NPs.
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The binding of GLU-NPs (1 × 109) to 1 × 105 RBCs was also tested in the presence
of various proportions of human plasma (0-100%) in PBS as mentioned above.
The involvement of GLUT1 transporter on the surface of RBCs in the binding of
GLU-NPs was evaluated by utilizing genistein, a competitive inhibitor of GLUT1. Briefly,
increasing concentrations of GLU-NPs were incubated with RBCs (1 × 105) in the presence
of genistein (100 µM) for 4 h at 37°C and 100 RPM. The number of NPs bound to RBCs
in the presence or absence of genistein was determined as described above.

2.3.5 Determination of RBC Lysis by GLU-NPs (In-vitro hematotoxicity)
To determine the effect of binding of NPs on the integrity of human RBCs, an increasing
number of NPs were incubated with 1 × 105 RBCs for 4 h at 37°C. The unbroken RBCs
were separated by centrifuging at 800g for 10 min. The NPs in the supernatant were cleared
by further centrifugation at 10,000g for 30 min. The lysis of the RBCs was quantified by
determining the absorbance of hemoglobin in the supernatant at 548 nm using a UV-visible
spectrophotometer (Molecular Devices SpectraMax Plus Microplate Reader). The percent
lysis was calculated by considering RBC lysis with 1 % Triton X-100 as 100 % and PBS
as 0 %.

2.3.6 Effect of Shear Stress on the Binding of NPs to RBCs
GLU-NPs were attached to the RBCs as mentioned under the in-vitro binding of NPs to
RBCs [103]. The NP labeled RBCs were sheared in a 25-mm plate and the plate rheometer
with a 0.1 mm gap (Paar Physica MCR300; Anton Paar, Ashland, VA). A solvent trap was
employed to prevent water evaporation. Cells were sheared at a constant shear stress of 2,
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5, 7 or 10 Pa for 30 min. The number of NPs attached on RBCs before and after the
application of the shear was determined using a fluorimeter (Molecular Devices
SpectraMax Plus Microplate Reader). In another experiment, after detachment using 5 Pa
for 30 min, the NPs were allowed to reattach for 4 h and the number of NPs attached were
determined as above [103].

2.3.7. In-vitro Binding of Protein to NPs using Immunoblotting
The in-vitro binding of proteins to NPs was studied by incubating NPs with 100 µl mouse
plasma for a period of 4 h at 37°C at 100 RPM. At the end of the incubation, NPs were
washed three times with PBS. The NPs were resuspended in sample buffer and the proteins
were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE). Proteins were then transferred onto a nitrocellulose membrane, and the blot was
blocked with 5% nonfat milk. The protein levels were detected and immunoblotted with
rabbit-anti-mouse Immunoglobulin (Ig) G antibody. The specific protein complexes were
identified using chemiluminescence detection kit and the intensities of the bands were
quantified [218, 219].

2.3.8. Incorporation of Fluorescence and Radioactive Markers in NPs
The conjugated NPs were radiolabeled as previously reported with modifications [80, 103,
107, 108]. Briefly, a 50 µl of 2% (w/v) GLU, HA and PEG conjugated NPs were swollen
in a mixture of 60 µl tetrahydrofuran (THF) containing 50 µl of 1 mCi/ml 3H-oleic acid
(for circulation time and biodistribution) or palmitic acid (for in-vivo binding of NPs to
RBCs) and 500 µl water. NPs were incubated for 30 mins at room temperature, washed
with water (~10 times) until no further radioactivity was detected in the supernatant. For
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in-vivo tumor targeting studies, the NPs were loaded with a near IR dye DiRC18 following
similar swelling method. The incorporation the dye was confirmed by spectroscopic
analysis at the excitation and emission wavelengths of 750 nm and 780 nm respectively.
The dye was incorporated to a similar extent in all the NPs [80, 103, 107, 108].

2.3.9. In-vivo Circulation Time and Biodistribution using Radiolabeled NPs
Female BALB/c mice (7 mice per group) were injected with 5 x 109 radiolabeled (3H-oleic
acid) NPs (GLU, HA, PEG conjugated) through the tail vein. Blood (50 µl) was collected
after pre-determined time-points post-injection (5, 20, 90, 240, 480 and 720 min) in
heparin-coated tubes, and plasma was separated by centrifugation. After 12 h of injection,
the mice were sacrificed by cervical dislocation, the blood was perfused with normal saline
and various organs were collected. The organs were homogenized in PBS at 1 g of tissue
per ml. Subsequently, the plasma and the tissues were digested using tissue solubilizer
(Biosol). The samples were mixed with 5 ml of Bioscint for plasma and 10 ml for tissues.
The percentage of initial dose still remaining in the blood and in various organs were
determined using the liquid scintillation counter (Beckman Coulter LS6500) [103].

2.3.10. In-vivo RBC Binding using Radiolabeled NPs
Female BALB/c mice (7 mice per group) were injected with 5 x 109 radiolabeled (3Hpalmitic acid) NPs (GLU, HA, PEG conjugated) through the tail vein. Blood (50 µl) was
collected after pre-determined time-points post-injection (at 2, 4, 8 and 12 h) in heparincoated tubes, centrifuged to separate blood cells. Blood cells were subsequently digested
using tissue solubilizer (Biosol). The samples were then mixed with 5 ml of Bioscint. The
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number of NPs bound to RBCs was determined using the liquid scintillation counter
(Beckman Coulter LS6500).

2.3.11. In-vivo Tumor Accumulation of Surface Modified NPs
Female BALB/c mice were used to study the tumor accumulation of surface-modified NPs
in-vivo. Allograft tumors were developed by injecting (1.5 × 106) 4T1 mouse breast cancer
cells in 200 µL PBS under the skin through subcutaneous injection on the left or the right
flank. All subcutaneous injections were given using a 25G needle and the hair was removed
with clippers prior to injecting the tumor cells. The animals were divided into three groups
and the NPs were administered. The mice were administered 4.54 × 108 particles/mouse
equivalent surface-modified GLU, HA and PEG conjugated NPs containing near-infrared
(IR) dye carbocyanine DiRC18 (Ex/Em 750/780 nm) through the tail vein [217, 220]. HANPs and PEG-NPs were utilized as control. The mice were imaged using Bruker-Xtreme
in-vivo imager before injection, 12 and 24 h post 1st injection. Another intravenous
injection of NPs was administered, and the mice were imaged again at 12, 24 and 48 h after
the 2nd injection. The intensity of the fluorescent signal was normalized and quantified
using Xtreme in-vivo imager software. The perimeter of the tumor is marked by using a
reflectance image.

2.3.12. Data Analysis & Statistics
All the experiments were performed in triplicate unless specified, and the results are
expressed as mean ± standard deviation unless specified. The variance between groups was
compared using Student’s t-test, one-way or two-way ANOVA as required followed by
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Bonferroni's or Dunnett's post-hoc multiple comparison tests (Instat, Graph Pad Software,
CA).

2.4. Results
2.4.1. Physicochemical Characterization of Polystyrene NPs
To investigate the possibility of using glucose for attaching the NPs on to RBCs,
polystyrene NPs conjugated with GLU on their surface were employed as a model. The
ligands GLU, HA, and PEG were conjugated to NPs with surface carboxylate groups using
EDC chemistry as represented in the Scheme 2-1. Polystyrene NPs with precise particles
size and shape, surface modified with HA and PEG, were carefully selected as controls to
rule out the role of particle size, shape, surface functional groups (-OH), charge, and
hydrophilicity on the functionality of GLU-NPs (Table 2-1). The average particle diameter
of the unconjugated NPs as recorded by DLS technique were 116.93 ± 0.76, 216.63 ± 2.10
and 542.13 ± 19.62 nm for NPs from commercial source labeled as 100, 200, and 500 nm,
respectively. The surface zeta potential of the unconjugated NPs was from -30 to -40 mV,
which is attributed to the presence of multiple surface carboxyl groups. The size of NPs
after conjugating to ligands was increased (Table 2-1). The average diameter of NPs was
altered to 246.73 ± 3.84 nm, 219.47 ± 2.66 nm and 288.33 ± 6.65 nm, for GLU-NPs, HANPs, and PEG-NPs, respectively. A similar pattern was observed with NPs of other sizes
(Table 2-1). The increase in hydrodynamic radii of the ligand conjugated NPs along with
the neutralization of surface charge of carboxyl groups is an indication of the successful
conjugation of the ligands. The NPs were found to be monodisperse as can be seen from
the polydispersity index values (Table 2-1).
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GLU/HA/PEG
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HOOC
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Scheme 2-1: Synthesis of surface-modified NPs using EDC chemistry.

Table 2-1: Physicochemical characterization of surface-modified NPs. The table
represents the diameter (nm), polydispersity index (PDI) and zeta potential (mV) of
polystyrene NPs. Data represent the mean ± standard deviation (n=3-4).
Groups

Diameter (nm)

PDI

ZP (mV)

Unconjugated 100 nm NPs

116.93 ± 0.76

0.02 ± 0.01

-29.15 ± 3.24

Unconjugated 200 nm NPs

216.63 ± 2.10

0.03 ± 0.009

-43.40 ± 0.30

Unconjugated 500 nm NPs

542.13 ± 19.62

0.19 ± 0.02

-38.87 ± 0.83

GLU-100 nm NPs

157.50 ± 36.81

0.30 ± 0.14

3.71 ± 1.34

GLU-200 nm NPs

246.73 ± 3.84

0.10 ± 0.01

9.61 ± 0.26

GLU-500 nm NPs

602.40 ± 163.0

0.63 ± 0.02

1.47 ± 1.22

HA-200 nm NPs

219.47 ± 2.66

0.07 ± 0.02

8.30 ± 4.85

PEG-200 nm NPs

288.33 ± 6.65

0.18 ± 0.01

9.19 ± 2.37
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2.4.2. GLU-NPs Bind to human RBCs In-vitro in a Concentration-dependent Manner
Human RBCs were incubated with surface modified fluorescent polystyrene NPs for 4 h
at 37°C. The number of NPs bound per RBC were quantified using fluorimeter. HA-NPs
or PEG-NPs were not able to bind in significant numbers to the isolated human RBCs
(Figure 2-1A). In contrast, GLU on the surface of NPs enabled them to bind to RBCs in a
concentration-dependent manner (Figure 2-1A) as shown using fluorimeter. The binding
of GLU-NPs of ~ 100, 200 and 500 nm in diameter to RBCs also demonstrated a
concentration-dependent binding (Figure 2-1C-E). The GLU-NPs bound to RBCs in
concentrated domains, as GLUT1 segregates in lipid-rich domains (Figure 2D insert) [221223]. The SEM images (Figure 2B(b)), further confirmed that GLU-NPs were bound to the
RBCs in clusters as compared to HA-NPs (Figure 2B(c)) and PEG-NPs (Figure 2B(d)),
which did not show any binding to the RBCs. Importantly, the ability of GLU-NPs to bind
to the RBCs in the presence of plasma represents the in-situ scenario post-injection in the
blood stream, which will make the strategy clinically feasible and relevant. When GLUNPs were incubated with RBCs in the presence of different proportions of plasma, the
GLU-NPs clearly demonstrated the ability to bind to the RBCs even at 100% plasma
concentration (Figure 2-2). The effect of the binding of GLU-NPs on the integrity and the
toxicity to human RBCs was evaluated using an increasing number of GLU-NPs in the
presence of a fixed number of human RBCs. The lysis of the RBCs was estimated by
determining hemoglobin released in the supernatant. Normal saline, RBCs treated with
saline and 1% Triton-X100 were utilized as controls. GLU-NPs did not cause any
detectable hemolysis up to 1×109 particles/million RBCs (Figure 2-3).
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B. Scanning Electron Microscopy of NPs
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Figure 2-1: In-vitro binding of NPs to RBCs. (A) 2.5×109 GLU, HA, and PEG-NPs were
incubated with 1×105 RBCs for a period of 4 h followed by washing and centrifugation at
800g to separate the RBCs bound with the NPs. The fluorescence of the RBCs was
measured in a 96 well black bottom plate at 580/605 nm. (B) Scanning electron microscopy
of NPs bound to RBC. In-vitro binding of GLU-NPs to RBCs. GLU-NPs-100 nm (C),
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GLU-NPs-200 nm (D) and GLU-NPs-500 nm (E). 1×109 -5×109 GLU-NPs were incubated
with 1×105 RBCs for a period of 4 h followed by washing and centrifugation at 800g to
separate the RBCs bound with the NPs. The fluorescence of the RBCs was measured in a
96 well black bottom plate at 580/605 nm using fluorimeter. Data represent the mean ±
standard deviation (n=3-4). Relative fluorescence unit (RFU).
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Figure 2-2: Binding of GLU-NPs to RBCs in the presence of plasma. 1×109 GLU-NPs200 nm were incubated with 1×105 RBCs in presence of varying concentrations of plasma
(0-100%) for a period of 4 h followed by washing and centrifugation at 800g to separate
the RBCs bound with the NPs. The fluorescence of the RBCs was measured in a 96 well
black bottom plate at 580/605 nm using fluorimeter. Data represent the mean ± standard
deviation (n=3-4). Relative fluorescence unit (RFU).
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Figure 2-3: The in-vitro hematotoxicity of NPs to RBCs. An increasing number of NPs
were incubated with 1×105 RBCs for a period of 4 h at 37°C and 100 RPM. Following the
incubation, the whole RBCs were separated from the NPs by centrifuging at 800g. The NPs
in the supernatant were cleared by further centrifugation at 10,000g for 30 min. The lysis
of the RBCs was estimated by determining hemoglobin released in the supernatant by
measuring the absorbance of the supernatant at 548 nm. 1% Triton-X100 and RBCs were
used as controls. Data represent the mean ± standard deviation (n=3-4).

2.4.3. The Binding of GLU-NPs to RBCs is GLUT1 Dependent
Once established that the surface GLU promotes the binding of polystyrene NPs to RBCs,
the role of GLUT1 on the membrane of RBCs in binding was investigated by quantifying
the binding in the presence of genistein, a known competitive inhibitor of the glucose-
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GLUT1 interaction [224, 225]. The RBCs were pre-incubated with 100 µM genistein
before the addition of GLU-NPs. Genistein inhibited the binding of GLU-NPs to RBCs
~60-80% when incubated with GLU-NPs (2.5 x 106 - 5 x 108) (Figure 2-4). The attachment
of GLU-NPs with RBCs was inhibited significantly by genistein, indicating that glucoseGLUT1 interaction may contribute to the surface attachment of GLU-NPs.

***
***
**

***

Figure 2-4: Binding of GLU-NPs to RBCs in the presence or absence of genistein. An
increasing number of GLU-NPs-200 nm were incubated with 1×105 RBCs in the presence
or absence of genistein (100 µM) for a period of 4 h followed by washing and
centrifugation at 800g to separate the RBCs bound with the NPs. The fluorescence was
measured in a 96 well black bottom plate at 580/605 nm using a fluorimeter. Data represent
the mean ± standard deviation (n=3-4). Relative fluorescence unit (RFU). ** and ***
indicates that the results are statistically significant at p < 0.01 and p < 0.001 as compared

63
to no genistein group calculated using two way-ANOVA followed by Bonferroni's multiple
comparison test.

2.4.4. The Binding of GLU-NPs to RBCs is Non-covalent and Reversible
The practicality of this approach rests heavily on the ability of the attached GLU-NPs to
have a reversible interaction with RBCs, which would allow them to reach the target tissue
for pharmacological action. RBCs usually experience shear stress of the magnitude ranging
between 0.01 to 14 Pa when squeezed through finer capillaries in the circulation [226].
Such shear has been shown to detach the surface-bound NPs. To simulate the conditions
in-vitro, we utilized a plate and plate viscometer to impart measurable stress to the NPs
bound RBCs. The stress of 2, 5, 7 or 10 Pa was applied over a time period of 30 min to the
NPs bound RBCs in plasma. The particles that remained attached to the RBCs were
subsequently quantified. The percent of particles detached at various shear stress (Pa)
ranged from 20 % at 2 Pa to 60 % at 10 Pa. The implementation of stress dislodged the
NPs from the surface of RBCs (Figure 2-5A). The GLU-NPs, which were dislodged from
the RBCs, were able to reattach after 4 h of incubation in absence of shear (Figure 2-5B).
The ability of the GLU-NPs to reversibly attach to RBCs could be critical in utilizing the
strategy for drug delivery.
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Figure 2-5: Reversibility of Binding. (A) Shear stress-induced particle detachment.
2×105 NPs were bound per 1×105 RBCs. The particle labeled RBCs were subjected to stress
in a plate and plate viscometer for a period of 30 min. (B) Reattachment of NPs after
removal of stress. 2×105 NPs were bound per 1×05 RBCs. The particle labeled RBCs were
subjected to shear stress in a plate and plate viscometer for a period of 30 min. Following
which they were allowed to rebind to the RBCs for 4 h. In both instances, the percentage
of particles detached and reattached was determined by measuring the fluorescence of the
RBCs at 580/605 nm using a fluorimeter. Data represent the mean ± standard deviation
(n=3-4). *This experiment was performed, and the data was generated by Pratik Muley.

2.4.5. GLU-NPs do not cause any Major Opsonization of Proteins
The in-vivo behavior and biodistribution of intravenous administered NPs are influenced
by the interaction of the particles with the blood proteins [227]. One factor that influences
the NPs-protein corona is the number of proteins that interact with the NP surface.
Immunoglobulin (Ig) G is by far one of the dominant proteins of the adsorption patterns,
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representing over 70% of the total detected protein amounts. IgG plays a very important
role in the opsonization related clearance of the intravenously injected particles [227-230].
We determined the amount of IgG bound to NPs using immunoblotting by incubating equal
amounts of NPs with mouse plasma for 4 h. GLU-NPs demonstrated significantly weak
protein adsorption, more specifically IgG as compared to HA-NPs and PEG-NPs. GLUNPs with ~100 nm diameter have shown higher IgG opsonization compared to GLU-NPs
with ~ 200 nm or 500 nm diameter (Figure 2-6). This may be due to the presence of a
greater number of NPs and larger surface energy per microgram of the NPs for 100 nm as
opposed to 200 nm/500 nm NPs. Relative to PEG-NPs, the GLU-NPs with ~100 nm
diameter showed ~65 % IgG opsonization, whereas GLU-NPs of 200 nm and 500 nm
diameter demonstrated ~48 % and 53% IgG opsonization (Figure 2-6).
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Figure 2-6: Protein adsorption patterns on surface-modified NPs. In-vitro
binding/adsorption of proteins (IgG-light chain) to surface-modified NPs in the presence
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of mouse plasma for a period of 4 h and the percentage protein adsorbed on surfacemodified NPs relative to PEG-NPs and HA-NPs. Data represent the mean ± standard
deviation (n=3-4). * indicates that the results are statistically significant at p < 0.05 as
compared to PEG-NPs-200 nm, calculated using two way-ANOVA followed by Dunnett’s
multiple comparison test.

2.4.6. GLU-NPs Bound to Mouse RBCs In-vivo
Once the binding of GLU-NPs to RBCs is established in-vitro, the concept was advanced
in-vivo using GLU-NPs loaded with radiolabeled palmitic acid (section 2.3.8). The surface
adsorbed palmitic acid was washed before injecting the particles. GLU, HA and PEG NPs
(5×109 particles/mouse) radiolabeled with (3H-palmitic acid) were injected by tail vein in
BALB/cJ mice. Blood was collected after pre-determined time points (at 2, 4, 8 and 12 h)
post-injection in heparin-coated tubes, centrifuged to separate the blood cells.
Subsequently, the blood cells were digested using a tissue solubilizer (Biosol) and mixed
with 5 ml of Bioscint. The number of NPs bound to RBCs was determined using the liquid
scintillation counter. The results demonstrate that GLU-NPs bound to RBCs in-vivo in
significant numbers as opposed to the HA-NPs and PEG-NPs at 4, 8 and 12 h post-injection
(Figure 2-7). Specifically, at 4 h and 8 h post-injection, ~1 (at p < 0.001) and 0.45 (at p <
0.05) GLU-NPs were bound per RBC as compared to HA-NPs and PEG-NPs (Figure 2-7).
On an average 0.3-1 GLU-NPs per RBC were bound 2-12 h post-injection. HA-NPs and
PEG-NPs showed considerably less binding than GLU-NPs. PEG-NPs demonstrate nonspecific binding at 2 h as can been seen from (Figure 2-7). GLU-NPs demonstrated
significantly higher efficiency of binding to RBCs because of the glucose-GLUT1
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interaction from the GLUT1 present on the RBC surface. The in-vivo binding of GLU-NPs
to GLUT1 on RBCs could potentially play a critical role in enhancing the circulation time
of NPs.
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Figure 2- 7: In-vivo binding of surface-modified NPs to RBCs. Surface modified NPs
(5×109 particles/mouse) radiolabeled with (3H-palmitic acid) were injected by tail vein in
BALB/cJ mice. Blood was collected after pre-determined time points (at 2, 4, 8 and 12 h)
post-injection and digested using tissue solubilizer (Biosol) and mixed with Bioscint. The
number of NPs bound to RBCs was determined using the liquid scintillation counter. Data
represent mean ± standard error of the mean (n=7 mice). *** and * indicates that the results
are statistically significant at p < 0.001 and p < 0.05 as compared to both HA-NPs and
PEG-NPs, respectively using two way-ANOVA followed by Bonferroni's multiple
comparison test.
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2.4.7. GLU-NPs Demonstrate Enhanced Systemic Circulation Time without Altering the
Biodistribution
One of the main goals of the study is to enhance the circulation time of NPs by hitchhiking
on to the RBCs using glucose-GLUT1 interaction. Therefore, the ability of conjugating
GLU on the surface of NPs in enhancing blood circulation time was assessed in mice using
GLU-NPs that are encapsulated with the radiolabeled oleic acid (section 2.3.8). Blood
samples were collected at pre-determined time intervals (at 5, 20, 90, 240, 480 and 720
min) and the radioactivity was measured using liquid scintillation counter. Various
pharmacokinetic parameters were calculated for GLU, HA, and PEG-NPs. The circulation
half-life (t50%) and the time required to clear 90% of the particles from the circulation (t90%)
of GLU-NPs was significantly higher than the HA, and PEG NPs (Figure 2-8A and C).
The T90% was ~7 h for GLU-NPs as compared to 4 h and 1 h for PEG-NPs and HA-NPs,
respectively (Figure 2-8C). The GLU-NPs demonstrated at least 2-fold (at p < 0.001)
longer circulation half-life as compared to the HA-NPs and PEG-NPs. The elimination rate
constant was much lower, and the volume of distribution was higher for GLU-NPs
compared to HA-NPs and PEG-NPs (Table 2-2). Thus, the presence of surface glucose
reduced the systemic clearance of NPs in mice.
The concentration of NPs in various organs was determined by isolating the organs
12 h post-injection and calculating the NPs remaining as % of injected dose (Figure 2-8B).
At the end of 12 h, all groups of NPs demonstrated a similar biodistribution in various
tissues including liver, kidney, lungs, spleen, and brain. This indicates that the general
pharmacokinetic distribution pattern of NPs did not alter by conjugating glucose on their
surface, however, glucose significantly improved circulation time.
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Figure 2-8: In-vivo circulation time and biodistribution of surface-modified NPs. (A)
Radiolabeled nanoparticles (3H-oleic acid) were injected by tail vein in BALB/cJ mice and
the percent of injected dose remaining was calculated and plotted against time. (B)
Biodistribution of surface-modified NPs. After 12 h of injection, the mice were sacrificed
by cervical dislocation, the blood was perfused with normal saline and various organs were
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collected. The percentage of initial dose still remaining in various organs was determined
using the liquid scintillation counter. (C) The pharmacokinetic parameters calculated
considering IV bolus dose and one compartment open model of the NPs. Data represent
the mean ± standard deviation (n=7 mice). *** and § indicates that the results are
statistically significant at p < 0.001 as compared to HA-NPs and PEG-NPs respectively
using two way-ANOVA followed by Bonferroni's multiple comparison test. *This
experiment was performed, and the data was generated by Pratik Muley.

2.4.8. GLU-NPs Demonstrate Increased Tumor Accumulation
Once the concept of enhancement of circulation time and binding of GLU-NPs to RBCs
was established in-vivo, we have studied the tumor accumulation of GLU-NPs by live
mouse imaging. The mice were divided into three groups and (4.54 × 108 particles/mouse)
equivalent surface-modified GLU, HA and PEG NPs loaded with a near IR dye DiRC18
were injected through the tail vein (Figure 2-9A). The incorporation of the dye was
confirmed by spectroscopic analysis at the excitation and emission wavelengths of 750 nm
and 780 nm respectively. The extent of GLU-NPs circulating in the body was significantly
higher as seen from the imaging results than HA-NPs or PEG-NPs (Figure 2-9B) at 12 h,
and 24 h post 1st injection (Figure 2-9B and C) and at 12 h, 24 h and 48 h post 2nd injection
(Figure 2-10B and C). The quantification of the results further demonstrate that GLU-NPs
has ~3 fold higher accumulation into tumors at 12 h and 24 h post 1st injection (at p ≤ 0.001)
and ~6 fold (at 12 h) and 3 fold (at 24 h) (at p ≤ 0.001) higher accumulation into tumors
as opposed to HA-NPs and PEG-NPs post 2nd injection respectively (Figure 2-10B and C).
Thus, GLU-NPs demonstrate higher tumor accumulation than HA-NPs and PEG-NPs
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(Figure 2-9B and C, Figure 2-10B and C). One of the possible reasons for the enhanced
tumor accumulation is that 4T1 tumors are known to overexpress GLUT1 transporter and
the GLU-NPs localized into the tumor utilizing a combination of passive, and active
targeting. Moreover, RBCs are known to have significantly higher GLUT1 transporter and
the results from the in-vivo pharmacokinetic study also demonstrate enhancement of
circulation time (Figure 2-8) and binding of GLU-NPs to RBCs (Figure 2-7). GLU-NPs
also showed considerably less opsonization of protein (IgG) than PEG-NPs (Figure 2-6).
Thus, GLU-NPs demonstrate enhancement in tumor accumulation due to the combined
passive, active targeting, reduced opsonization, and enhancement in circulation time.
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Figure 2-9: In-vivo tumor accumulation of surface-modified NPs after 1st injection.
(A) Scheme for in-vivo administration of surface-modified NPs. The mice were inoculated
with 4T1 (1.5×106) breast cancer cells via subcutaneous injection. GLU, HA, and PEG NPs
(4.54×108 particles/mouse) were encapsulated with near IR dye DiRC18 and administered
IV to BALB/cJ mice. The mice were subjected to tumor imaging at various predetermined
time points (before injection, at 12 and 24 h) using a Bruker in-vivo imager. (B)
Representative in-vivo fluorescence images (before injection, 12 and 24 h) obtained after
time-lapse imaging using a Bruker in-vivo imager. The mice were anesthetized using
isoflurane before imaging. The scale represents normalized intensities. The red circle
indicates the tumor site. (C) Quantification of tumor accumulation of surface-modified
NPs. The amount of NPs in the tumor was quantified after normalizing the intensities using
Bruker MI software. The data represents mean fluorescence intensities at various time
points. Data represent the mean ± standard deviation. *** and § indicates that the results
are statistically significant at p < 0.001 as compared to HA-NPs and PEG-NPs respectively
using two way-ANOVA followed by Bonferroni's multiple comparison test.

75

A. Scheme for in-vivo Tumor Accumulation
Subcutaneous 4T1 cancer
cells (1.5 106)

NPs with near IR DiRC18 dye
IV

Day 17

Day 0

In-vivo tumor imaging
using Bruker in-vivo
imager

B. In-vivo Tumor Accumulation
12 h

48 h

PEG-NPs

HA-NPs

GLU-NPs

24 h

C. Quantification of Tumor Accumulation
~ 6 times

300

GLU-NPs
HA-NPs
PEG-NPs

***

250

MFI

200

~ 3 times

150
***

100
50
0

12

24

Time (h)

48

76
Figure 2-10: In-vivo tumor accumulation of surface-modified NPs after the 2nd
injection (day 17). (A) Scheme for in-vivo administration of surface-modified NPs. The
mice were inoculated with 4T1 (1.5×106) breast cancer cells via subcutaneous injection.
GLU, HA, and PEG NPs (4.54×108 particles/mouse) were encapsulated with near IR dye
DiRC18 and administered IV to BALB/cJ mice. The mice were subjected to tumor imaging
at various predetermined time points (at 12 h, 24 h, and 48 h) using a Bruker in-vivo imager.
(B) Representative in-vivo fluorescence images (at 12 h, 24 h, and 48 h) obtained after
time-lapse imaging using a Bruker in-vivo imager. The mice were anesthetized using
isoflurane before imaging. The scale represents normalized intensities. The red circle
indicates the tumor site. (C) Quantification of tumor accumulation of surface-modified
NPs. The amount of NPs in the tumor was quantified after normalizing the intensities using
Bruker MI software. The data represents mean fluorescence intensities at various time
points. Data represent the mean ± standard deviation. *** and § indicates that the results
are statistically significant at p < 0.001 as compared to HA-NPs and PEG-NPs respectively
using two way-ANOVA followed by Bonferroni's multiple comparison test.
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2.5. Discussion
The short half-life of nanoparticles in the systemic circulation is a major roadblock in
advancing the intravenously injected nanomedicine for both imaging and/or drug delivery
[80, 103, 107, 108, 189, 196, 197]. Particulate delivery systems are foreign in nature and
therefore, are quickly recognized and eliminated by MPS of the immune system such as
circulating monocytes and macrophages of the liver, spleen, lung, and bone marrow [231,
232]. This study provides a unique strategy of trapping NPs on the surface of RBCs with
natural, reversible, non-covalent interaction to evade rapid clearance and making them
available at capillaries for efficient accumulation and targeting for cancer therapeutics
and/or imaging [75]. In this study, polystyrene NPs were surface modified with glucose
(GLU-NPs) to interact with GLUT1 transporter on the membrane of RBCs, thereby
enhancing systemic circulation time and tumor accumulation [208].
Three major physiological mechanisms are involved in the clearance of particulate
matter form the circulation; opsonization by plasma proteins (opsonin’s), phagocytosis by
cells of the MPS, and renal filtration. Opsonization enhances recognition by phagocytic
cells and accelerates clearance [75, 112, 233-237]. Together, they constitute a potent
mechanism to clear pathogens and particles from the circulation, as early as 10 minutes
[231, 233, 234, 238]. Numerous strategies have been designed to target specific/multiple
mechanisms of clearance mentioned above. For example, increasing the size of NPs more
than 10 nm has generally been shown to reduce the renal clearance [239, 240]. In this study,
we have selected spherical polystyrene NPs of around 200 nm diameter to represent the
majority of the nano-drug delivery systems currently being investigated, which is expected
to reduce renal filtration.
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The existing state-of-the-art technology to prolong the circulation of NPs targets
opsonization and utilizes surface modification with hydrophilic polymers or proteins [7779]. Since opsonin’s preferentially bind to hydrophobic surfaces, modification with a
hydrophilic polymer provides a repulsive and/or steric barrier to reduce the opsonization
[78]. The polymer of choice for such applications has been PEG [79, 86, 87, 89, 90].
PEGylation increases the circulation time of various nanocarriers including
polymeric/inorganic NPs, liposomes, micelles and macromolecules [85, 89, 90, 203].
However, recent studies point toward an anomalous behavior of PEGylated nanocarriers.
Repeated administration of PEGylated nanocarriers to animals (mice [91], rats [94],
beagles [99] and rhesus monkey[97]) resulted in an unexpected “Accelerated Blood
Clearance” (ABC) mainly due to the generation of anti-PEG-IgM antibodies from splenic
B-cells [95, 98, 241-243]. ABC is a phenomenon where the clearance rates of the carriers
from the bloodstream are raised upon repeated injections [91, 94, 97]. Furthermore,
PEGylation potentially interferes with the interaction of the nanocarriers to the target cells,
thereby reducing the efficiency of the intended therapy [93]. More importantly, the cost of
the technology also plays a significant role to translate the potential of nanomedicine from
laboratory to patient. Mono and bi-functional PEGs commonly used in PEGylation are very
expensive and add significantly to the cost of the final product. Moreover, toxicological
studies have shown that PEG could lead to an increased tendency to cause blood clotting
and clumping of cells [93, 203].
In this study we have addressed the drawbacks with PEGylation by surface
modification of NPs using glucose with the following evidence/rationale(s): (i) being a
smaller endogenous ligand, glucose is not expected to evoke antibody response or undergo
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ABC-mediated removal from circulation; (ii) glucose is safer than synthetic
macromolecules (iii) glucose conjugation reduced opsonization much better than
PEGylation (Figure 2-6); (iv) as glucose is a ligand for active targeting for cancer cells
[145, 163, 174, 182, 244], it improves the interaction and accumulation of NPs in the cancer
tissue, thereby demonstrating increased tumor accumulation (Figure 2-9 and 2-10) (v)
modifying NPs with glucose imparts an ability to hitchhike on RBCs (Figure 2-8), which
has been recently discovered as an efficient strategy for enhanced circulation time [80, 86,
103-105, 107, 108, 113]. GLU-NPs enhanced the circulation half-life of NPs by ~2 fold
compared to PEG-NPs without the drawback associated with PEGylation.
The circulation time of the particulate delivery system depends on multiple
physicochemical properties of NPs such as size, shape, surface functionality (a charge,
functional groups), and mechanical properties [46, 198, 245-248]. In addition, NPs could
also bind to the membrane of RBCs non-specifically depending on their physicochemical
properties [103]. The role of the above parameters in the binding of GLU-NPs to RBCs
and improved clearance time were ruled out by using control NPs that are surface
conjugated with hydroxylamine (Table- 2-1). GLU-NPs showed a significant increase in
binding to human RBCs in-vitro even in the presence of plasma (Figure 2-1 and 2-2) and
to mouse RBCs in-vivo (Figure 2-7) indicating the specific role of glucose in the interaction
with the RBCs. The involvement of GLUT1 in the binding of GLU-NPs to RBCs was
further confirmed by the inhibition of binding in the presence of genistein, a competitive
inhibitor of glucose-GLUT1 interaction (Figure 2-4). GLU-NPs bound to RBCs in clusters
(Figure 2-1), which may be due to the localization of GLUT1 in microdomains of lipid
rafts [221-223].
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For a strategy based on hitchhiking on RBCs to improve circulation time, it is
essential for particles to detach from RBCs before reaching the target tissue unless the
target tissue is the blood. Since the physiological interaction of glucose with GLUT1 is
non-covalent and transient [249], the majority of GLU-NPs bound to GLUT1 of RBCs
were detached when a shear of 10 Pa was applied. The shear stress employed is similar to
the stress experienced by RBCs during their passage through circulation (0.01 to 14 Pa).
The ability of the GLU-NPs to detach from the RBCs under shear stress and then reattach
when stress is removed might be a key factor in the accumulation of GLU-NPs in target
cancer tissue (Figure 2-5A and B) [103]. Such detachment also supports the data that GLUNPs were almost cleared from the circulation after 12 h (Figure 2-8) despite having an
improved circulation half-life compared to PEGylated NPs (Figure 2-8C)
RBCs are one of the highly studied endogenous cells used as drug delivery vehicles
because of their biocompatibility, abundance, ease of manipulation and long-circulating
half-life [86, 113]. Indeed, several pathogens such as hemobartonella (Mycoplasma
haemofelis), eperythrozoonosis and Plasmodium falciparum utilize RBCs as carriers to
evade immune-clearance. These pathogens remain in circulation for weeks to months by
attaching themselves onto the surface of RBCs [204-206]. Such strategy from nature has
been explored previously by us and other groups to create stealth nanoparticles and
targeting to specific organs [110, 111, 115, 118, 250-252]. The work reported here will
provide practical feasibility to the approach by using physiological interactions between
glucose and GLUT1 on RBCs.
In addition, GLUT1 is uniquely positioned for enhanced circulation time as well as
tumor accumulation for cancer therapeutics since it is over-expressed in multiple cancer
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types [145, 151, 153, 179, 187, 253-255]. In addition, to serve the needs of the rapidly
growing cancerous tissues, through the release of vascular endothelial growth factor
(VEGF) and other factors by the cancer cells, rapid vascularization is promoted. Such rapid
vascularization often leads to a leaky and defective vascular architecture devoid of the
basement membrane and impaired lymphatic drainage. The abnormal fenestrations in the
cancer vasculature allow the nanocarriers to leak into cancerous tissues, sparing the normal
tissues [41, 42, 256]. Since the cancer tissues lack a well-developed lymphatic drainage
capability, NPs that enter are retained within the tissues for prolonged periods of time. This
phenomenon is called the enhanced permeability and retention (EPR) effect [42]. We
hypothesize that the GLU-NPs that are attached to the RBCs, eventually detach from it at
fine capillaries because of shear forces and cellular interactions (Figure 2-11).

Figure 2-11: Schematic diagram representing an enhancement of circulation time and
tumor accumulation by GLU-NPs through an attachment on to RBCs.
Upon detachment, the NPs may enter the cancer tissues through EPR effect and will be
retained for prolonged periods of time for better tumor accumulation (Figure 2-8). Similar
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results were obtained through in-vivo tumor accumulation which depicts that GLU-NPs
demonstrates higher tumor accumulation (~3-6 folds) post 1st and 2nd injection in mice
bearing 4T1 breast cancer tumors (Figure 2-9 and 2-10). Several factors may have
contributed for enhanced accumulation of GLU-NPs in the tumor tissue: a) longer
circulation time; b) passive targeting through EPR effect; and c) since 4T1 cells
overexpress GLUT1, the penetrated GLU-NPs may have been retained through active
targeting.

2.6. Conclusions
In conclusion, we have developed a novel and unique strategy to enhance the systemic
circulation time and tumor accumulation of polymeric NPs through an attachment on to
the surface of RBCs through GLUT1 transporters. As the interaction of glucose to GLUT1
is physiological, GLU-NPs interaction with GLUT1 is non-covalent, reversible, occurs
even in the presence of plasma and importantly, extended to in-vivo conditions. In addition,
natural nutrient glucose is not expected to develop antibodies or toxicity. Moreover, since
several cancers overexpress GLUT1, the same interaction also benefits to preferentially
accumulate NPs in the tumors as shown from the in-vivo tumor accumulation studies. In
addition to cancer, the concept is also applicable for various other applications such as
tumor imaging, sustained drug delivery, and targeting to other tissues. Furthermore, the
versatility of this approach could be applicable to potentially any nanoparticulate delivery
system to enhance their circulation and potentially impact a wide variety of research in
diverse fields.
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CHAPTER III

INDUCED TRANSPORTER-MEDIATED ENDOCYTOSIS (TME):
IMPLICATIONS IN CANCER-TARGETED DRUG DELIVERY
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3.1. Introduction
Cancer, one of the leading causes of mortality in the United States (US), is a heterogeneous
group of diseases involving complex molecular alterations at the cellular level. The clinical
therapy of cancer using the traditional chemotherapeutic drugs is not satisfactory due to
serious adverse effects and the higher risk of developing drug resistance [1, 2, 5] [3, 4, 610]. One of the primary goals of the current research in cancer therapeutics is to either
identify cancer-specific targets for new drug discovery (targeted therapies) or to deliver
the existing chemotherapeutic drugs specifically to the cancer cells (targeted drug
delivery). Targeted drug delivery is an economical and quicker approach than targeted
therapies to address the urgent unmet need for safe cancer therapeutics [13, 14, 257]. The
current approaches for targeted drug delivery primarily focuses on two principles:
delivering large drug cargo through particle-based drug delivery systems instead of small
molecular drugs and modifying the delivery system to interact specifically with the
receptors that are overexpressed in cancer cells compared to normal cells [14, 23, 34, 43,
44, 59, 66, 69]. Despite having tremendous success in preclinical studies, the progress of
this (receptor-based active targeting) strategy has been challenging for clinical translation.
Some critical challenges include rapid clearance of particulate delivery systems, variability
in receptor expression patterns and complexity with the ligand structures [127, 258-261].
Therefore, the recent focus has been to identify alternate molecular targets, having small
and stable ligands, that are differentially expressed in cancer cells [65, 127].
Rapid proliferation, poor vasculature, and hypoxia have been the key hallmarks of
cancer cells. Rapid cell proliferation increases the demand for nutrients (glucose, amino
acids, vitamins, and fatty acids), which serves as the carbon source for the synthesis of
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DNA, RNA and as a source of metabolic energy. Switching the metabolic pathways from
mitochondrial oxidative phosphorylation to glycolysis under hypoxic conditions is an
important adaptive mechanism for cancer cells, which requires excess amounts of
intracellular glucose [129]. This increased demand for glucose often leads to high levels of
expression and activity of cell surface glucose transport proteins (GLUTs) [143].
GLUT1 is the most ubiquitous and extensively studied glucose transporter among
the 14 members of the GLUT family. GLUT1 is a key rate-limiting factor in the transport
and metabolism of glucose in cancer cells [129, 142, 145, 151, 160, 179]. Importantly,
GLUT1 is overexpressed in a number of cancer types including breast, brain, ovarian,
hepatic, pancreatic, esophageal, renal, lung, cutaneous, colorectal, endometrial, bladder,
cervical, hepatocellular, head and neck and gastric cancers [138, 145, 151]. Its expression
is also positively correlated with increased malignant potential, metastasis, differentiation,
and invasiveness of the tumor along with poor prognosis and poor overall survival of the
patient [139, 141, 144, 145, 151, 153, 155, 158, 167, 187, 262]. For example, breast cancer
has demonstrated increased expression of GLUT1, with as high as 91% positive staining
of the invasive ductal carcinomas as compared to the control [61, 153-157, 263]. Due to
the above reasons, GLUT1 has been recognized as a prognostic marker and explored for
in-vivo tumor diagnosis using

18

F-fluoro-2-deoxy-D-glucose in positron emission

tomography (PET) [167, 174].
In addition, glucose as a ligand on nanocarriers provides several advantages over
ligands for receptors with respect to targeted drug delivery. Most of the ligands for
receptors are macromolecules such as monoclonal antibodies. They require to maintain the
structural conformation for effective binding to receptors, which might be challenging after
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chemical conjugation to nanocarriers and/or after long storage. Furthermore, glucose is a
stable ligand and does not evoke an immune response, unlike macromolecular ligands. It
doesn’t add to the bulkiness of the nanocarriers and therefore, it does not compromise the
advantage(s) of passive targeting of nanocarriers through enhanced permeation and
retention effect (EPR effect). Recently, we have developed a long-circulating nanocarrier
system (stealth) by conjugating glucose onto their surface, which enables them to attach
onto the outer membrane of red blood cells (RBCs) through surface-expressed GLUT1
[208]. The modification of nanocarriers with glucose on the surface significantly enhanced
the blood circulation time of NPs in mice compared to PEGylated NPs, the current stateof-art technology (chapter II). The enhanced circulation of glucose conjugated nanocarrier
is hypothesized to facilitate the accumulation of NPs in cancer tissues, which has leaky
vasculature.
To further advance the technology for cancer management, in this study, we have
demonstrated the feasibility of glucose-modified nanoparticles (GLU-NPs) as a smart drug
delivery system to differentiate breast cancer cells from normal cells based on the
expression levels of GLUT1. Glucose is conjugated onto the surface of nanoparticles
(GLU-NPs) in a confirmation that retained the ability to bind to GLUT1. GLU-NPs
delivered significantly higher cargo to breast cancer cells (MDA-MB-231 and 4T1)
compared to the control NPs. The bound GLU-NPs were internalized into cancer cells,
which was specifically dependent on the glucose-GLUT1 interaction and involves
caveolae-mediated endocytosis for subsequent transport into the lysosomal compartment.
To further demonstrate the translation of the technology to cancer therapeutics, we have
synthesized poly(lactic-co-glycolic acid) conjugated to glucose (PLGA-GLU) as a novel
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functional polymer. The NPs prepared with PLGA-GLU (PLGA-GLU-NPs) showed the
ability to differentiate breast cancer cells (MDA-MB-231 and MCF7) versus non-cancer
cells (MCF10a) based on the expression levels of GLUT1. The in-vivo tumor accumulation
of GLU-NPs was evaluated in an allograft mouse model (4T1 breast cancer) using imaging
techniques. Thus, through a proof-of-concept and mechanistic analysis, we demonstrate
the feasibility of employing GLUT1 transporters as a novel approach for cancer-targeted
delivery.

3.2. Materials
3.2.1. Chemicals and Reagents
Fluorescent polystyrene particles with surface carboxyl groups (100, 200 and 500 nm in
diameter) and Alexa Fluor™ 488 Phalloidin (A12379) were purchased from Life
Technologies Inc. (Portland, OR, USA). Tetrahydrofuran, 2-amino-2-deoxy-D-glucose
(GLU), hydroxylamine (HA), genistein, 1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide
(EDC), and poly(lactic-co-glycolic acid) (PLGA RG-653H) were purchased from Sigma
Aldrich (St. Louis, MO, USA). Regional Blood Bank, (Sioux Falls, SD, USA) gifted
human RBCs. 3H-labeled oleic acid was purchased from Moravek, Inc. (Brea, CA, USA).
GLUT1 rabbit monoclonal antibody (12939S) was obtained from Cell Signaling
Technology (Danvers, MA, USA). The DiOC18 dye, snakeskin dialysis membrane (10 kDa
cutoff), MES hydrate, N-Hydroxysuccinimide (NHS), Nile red, polyethylene glycol of
M.Wt. 2000 (PEG2000), and all other biochemical reagents, solvents, and supplies were
purchased from Fisher Scientific (Pittsburgh, PA, USA).
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3.2.2. Cell Lines and Cell Culture
4T1 (Mouse breast cancer), MDA-MB-231 (Human breast cancer), OVCAR3 (Human
ovarian cancer), ID8 (Mouse ovarian cancer), HCT116 (Human colorectal carcinoma),
PC3 (Human prostate cancer), MCF7 (Human breast cancer), MCF10a (Breast epithelial
cells), NCI-H226 (human lung squamous carcinoma), LnCAP (Human prostate cancer)
and SKMEL-2 (Human malignant melanoma) were purchased from the American Type
Culture Collection (ATCC) (Manassas, VA, USA). The cells were cultured in Dulbecco's
Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute (RPMI-1640)
medium based on the recommendations of ATCC in a humidified atmosphere of 5% CO2
at 37ºC. The culture media also contained 10% fetal bovine serum (FBS) and
penicillin/streptomycin.

3.2.3. Animals
All animal experimentation was performed in compliance with the regulations of the
Institutional Animal Care and Use Committees (IACUC) of the South Dakota State
University, Brookings, SD, USA.

3.3. Methods
3.3.1. Surface Modification of NPs
The polystyrene NPs with carboxyl surface groups were conjugated with GLU, HA, and
PEG2000 by using EDC chemistry [212, 213]. The NPs conjugated with glucose, HA,
PEG2000 are denoted as GLU-NPs, HA-NPs, and PEG-NPs from here after. Unless
specified, GLU-NPs stands for NPs with around 200 nm in diameter. The GLU-NPs-100
and GLU-NPs-500 indicate glucose conjugated NPs with a diameter of around 100 nm and
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500 nm, respectively. Briefly, a 50 µl of polystyrene NPs from a 2% w/v suspension was
washed with 50 mM MES buffer (pH 6.0) three times and resuspended in 400 µl of the
MES buffer. The carboxylic acid groups were activated by adding EDC (7.5 mg) and
incubating for 10 min at room temperature. Subsequently, 25 mg of GLU/HA/PEG2000 in
MES buffer was added to the suspension and the reaction was carried out at room
temperature in dark. After 4 h, the NPs were collected by centrifugation at 20,000g for 30
min and washed thrice with 50 mM phosphate-buffered saline, pH 7.0 (PBS). The NPs
were stored at 4°C in the presence of 20 mM sodium azide and 0.001 % Triton X-100 until
further analysis.

3.3.2. Characterization of NPs: Size, Surface Charge, and Morphology
3.3.2.1. Dynamic Light Scattering (DLS): The average size, polydispersity index and the
surface charge (-potential) of NPs were determined using the DLS technique. Initially, the
NPs were dispersed by bath sonication in filter-sterilized 10 mM phosphate buffer (pH 7.4)
and then further diluted (1:10) using deionized water before recording particle size and potential using Malvern Zeta-Sizer, Malvern Ltd, MA, USA [214, 215, 217].
3.3.2.2. Scanning Electron Microscopy (SEM): Scanning electron microscope (SEM,
Model S-3400N, Hitachi, Japan) was used to investigate the shape and the morphology of
GLU-NPs, HA-NPs, and PEG-NPs. For the preparation of samples, a smear of the NPs
was created on a glass slide using a suspension of NPs in filter-sterilized water and a section
of glass slide was mounted on the metal holder using conductive double-sided tape. The
particles were sputter-coated with a 10-nm gold layer before analysis. The micrographs
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were captured at an accelerating voltage of 20 kV, with a working distance of 10–15 mm
and a spot size of three [214, 215, 217].

3.3.3. In-vitro Binding of NPs to RBCs
The in-vitro binding of GLU-NPs with human RBCs was determined by incubating an
increasing number of NPs with 1 × 105 RBCs in sterile PBS for 4 h at 37°C and 100 RPM.
The RBCs were separated from unbound NPs by centrifugation at 800g for 10 min and
washing three times with sterile PBS. The number of NPs bound to RBCs was determined
by measuring fluorescence at Ex/Em wavelengths of 580/605 nm using a fluorimeter
(Molecular Devices SpectraMax Plus Microplate Reader). Precautions were taken to
minimize light exposure to NPs [208].

3.3.4. Microscopic Analysis of Internalization of GLU-NPs by Cancer Cells
The internalization of GLU-NPs by various cancer cells (MDA-MB-231, NCI-H226,
LnCAP, and SKMEL-2) was studied as described below. Brieﬂy, 1 105 cells were seeded
on glass coverslips in 6 well-plates and allowed to adhere for 24 h. Subsequently, the cells
were incubated with medium, GLU-NPs or HA-NPs for 4 h at 37°C and 5 % CO2. After
incubation, the cells were washed thrice with PBS and fixed with freshly prepared 4 % w/v
paraformaldehyde (PFA) for 10 min. The actin was stained with Alexa Fluor™ 488
Phalloidin and the nucleus with 4′,6-diamidino-2-phenylindole (DAPI). The coverslips
were mounted using ProLong™ Gold Antifade mounting medium (P10144). The images
were collected under a fluorescence or confocal microscope [215].
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3.3.5. In-vitro Quantitative Cell Uptake of GLU-NPs by Breast Cancer Cells
In-vitro quantitative cell uptake of GLU-NPs by MDA-MB-231 cells was evaluated by
flow cytometry. Untreated cells or cells treated with HA-NPs were employed as controls.
Brieﬂy, 1 105 cells/well were seeded in 24 well-plates. After 24 h, the cells were treated
with medium, GLU-NPs or HA-NPs at 91.24 × 109 particles in 1 ml of cell culture medium
at 37°C and 5 % CO2. At different time points (0.5-4 h), cells were washed with PBS and,
trypsinized. The cells were fixed using 4 % PFA and stored at 4°C in PBS until further
analysis. Sample acquisition was performed using BD Biosciences FACS LSR Fortessa
using the excitation laser of 561 nm and the red fluorescence channel. The data were
analyzed using CellQuest Pro Software (BD) [214, 215, 217].

Similarly, GLU-NPs of various sizes (~100 nm, 200 nm, and 500 nm) were used to
study the effect of the diameter of the NPs on the uptake. Untreated cells were employed
as controls. The experiment was performed, and the cells were processed as mentioned in
the above paragraph. An equal number of GLU-NP-100 nm, GLU-NPs-200 nm and GLUNPs-500 nm NPs (91.24 × 109 particles) was added to the cells during this experiment.

The specificity of internalization of GLU-NPs by MDA-MB-231 cells was studied
using a mixture of NPs with a unique combination of surface modification (HA or GLU)
and fluorescence markers (red and/or blue). Brieﬂy, 1 105 cells in a 6-well plate were
incubated with medium or the combination of HA-NPs and GLU-NPs containing different
fluorescent markers at 37°C and 5 % CO2. After 4 h, the cells were washed thrice with
PBS, and fixed with 4 % w/v PFA for 10 min and observed under a confocal microscope
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using the appropriate set of filters. The excitation/emission wavelengths for red and blue
particles were 580/605 nm and 365/415 nm, respectively.

3.3.6. Immunoblotting
We evaluated the GLUT1 expression levels of various cancer cells using immunoblotting.
The total cell protein content from the cells was extracted using 0.25 mL of cold fresh lysis
buffer [1% Triton X-100, 150 mM NaCl, 0.5 mM MgCl2, 200 mM EGTA, and 50 mM
Tris-HCl (pH 7.4) with aprotinin (2 mg/mL), Dithiothreitol (DTT, 2 mM), and
phenylmethylsulfonyl fluoride (PMSF, 1 mM)] by incubating on ice for 30 min [218, 219].
The soluble lysate was separated by centrifugation at 20,000g for 10 min. The protein
content in the lysates was estimated using Bicinchoninic acid assay (BCA) (Pierce™ BCA
Protein Assay Kit). Around 50 µg of proteins from lysates were separated on an 8-10%
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) under reducing
conditions. Proteins were then transferred onto a nitrocellulose membrane, and the blot was
blocked with 5% nonfat milk [218, 219]. The protein levels were detected by
immunodetection with GLUT1 specific antibody (1:1500 dilution). The specific protein
complexes were identified using chemiluminescence detection kit.
We further elucidated the interaction of GLU-NPs with GLUT1 by an affinitypulldown assay. In brief, MDA-MB-231 cells were incubated with GLU-NPs representing
various sizes (100 nm, 200 nm, and 500 nm) and HA-NPs (200 nm). After 4 h of
incubation, the cells were washed with PBS to remove unbound NPs. The cells were lysed
using lysis buffer, centrifuged at 20,000g for 30 min to separate NPs from the lysate. The
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NPs were washed thrice with PBS and the proteins associated with the NPs were separated
using SDS-PAGE as described in the above paragraph.

3.3.7. In-vitro Cell Uptake of GLU-NPs in the Presence or Absence of GLUT1 Inhibitors
Brieﬂy, 1 105 cells/well were seeded in 24 well-plates. After 24 h, the cells were treated
with genistein (10 µM and 200 µM) or cytochalasin B (200 µM) for 30 min in the presence
of serum-free low glucose DMEM medium. Subsequently, GLU-NPs (91.24 × 109
particles) were added to the cells to further incubate for 3 h at 37°C and 5 % CO2. The cells
without pre-treatment with inhibitors were used as controls. The efficiency of
internalization of NPs was quantified using flow cytometry as described in section 3.3.5.
and qualitative images were collected as described in section 3.3.4.

3.3.8. Studying the Endocytosis Pathway(s) involved in the Cell Uptake of GLU-NPs
Pharmacological inhibitors were employed to determine the endocytic pathway(s)
responsible for cell uptake and internalization of the surface-modified NPs. MDA-MB-231
cells were incubated with previously optimized doses (in terms of toxicity) of chloroquine
diphosphate (100 μM), dynasore (100 μM), nystatin (100 μM), rottlerin (5 μM) and
nocodazole (20 μM) for 30 min in the presence of serum-free low glucose DMEM medium
[264, 265]. Subsequently, GLU-NPs (91.24 × 109) were incubated with cells for 4 h at
37°C in the continuous presence of inhibitors. Cells treated with medium or only GLUNPs without inhibitors were employed as controls. Internalization of NPs was studied using
flow cytometry as mentioned in section 3.3.5.
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To elucidate the destination of GLU-NPs after internalization, MDA-MB-231 cells
were seeded onto 6-well plates (5×104 cells/well). After 24 h, the cells were transfected
with Lamp1 (lysosomal-associated membrane protein 1) tagged with a green fluorescent
protein (GFP) using CellLight® Reagent BacMam 2.0 baculovirus vector for 16 h as per
the instructions provided by the supplier (Life Technologies Inc.). Subsequently, GLUNPs were added to the cells. After 4 h, cells were washed three times with PBS and the
cells were imaged using fluorescence and/or confocal microscope with appropriate filters.

3.3.9. Synthesis of Glucose Conjugated PLGA Polymer
One gram of PLGA–carboxylate (PLGA RG-653H) was dissolved in 5 ml methylene
chloride. To this, NHS (27 mg) and EDC (26 mg) dissolved in 2 ml methylene chloride
were added. PLGA–NHS was precipitated with the addition of 10 ml of ethyl
ether/methanol (1:1 ratio). The precipitated PLGA–NHS was washed with ethyl
ether/methanol mixture thrice and collected by centrifugation at 4000g for 20 min. The
PLGA–NHS pellet was dried under vacuum for 1-2 h to remove the residual solvents.
Subsequently, PLGA–NHS was dissolved in methylene chloride (4 ml) followed by
addition of GLU (100 mg) and triethylamine (17 µl). The resulting polymer was
precipitated in and washed with deionized water. The pellet was dried under vacuum and
used for the NP preparation [266]. The formation of PLGA-GLU was confirmed by Fourier
transform infrared (FTIR), proton nuclear magnetic resonance spectroscopy (NMR), and
powder X-ray diffraction (PXRD) analysis.
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3.3.10. Characterization of the Polymer:
3.3.10.1. FTIR Spectroscopy: The conjugation of GLU to PLGA was confirmed by
recording the FTIR spectrum. The FITR spectrum of GLU, PLGA RG-653H, and PLGAGLU were recorded between 4000 cm−1 and 400 cm−1 at a resolution of 4 cm−1 using
Nicolet 380 ATR-FTIR spectrophotometer (Thermo Electron Corp., Madison, WI). The
average of 50 scans of data is represented [214, 215, 217, 267].
3.3.10.2. NMR Spectroscopy: To confirm the conjugation of GLU to PLGA, 1H-NMR
spectra of GLU, PLGA RG-653H, and PLGA-GLU were recorded on a Bruker 600 MHz
NMR spectrometer. Briefly, 30 mg of the compound was dissolved in DMSO-d6 and the
NMR spectra were recorded for all the solutions [214, 215, 267].
3.3.10.3. PXRD Analysis: Powder X-ray diffraction measurements of the polymers: PLGA
RG-653H and PLGA-GLU were recorded. All measurements were recorded using Rigaku
powder x-ray diffractometer with copper (Cu) radiation, running at 40 kV and 44 mA. For
this study, samples were mounted on double-sided silicone tape and measurements were
performed from 2°C to 60°C at a scan speed of 4°C/min and increments of 0.02°C [215,
267].

3.3.11. Preparation of PLGA and PLGA-GLU-NPs: PLGA and PLGA-GLU-NPs
encapsulated with Nile red (model hydrophobic dye) or 3H-labeled oleic acid were
prepared by the solvent evaporation technique. The PLGA-GLU polymer (100 mg) and
Nile red (10 mg) was dissolved in 5 ml of dichloromethane (DCM). The solution was then
added dropwise into an aqueous phase containing 30 ml deionized water and 0.5% w/v
PVA with continuous stirring for approximately 12-16 h. The precipitated particles were
collected via centrifugation at 50,000 g for 30 min at 4°C. The collected particles were
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washed and re-suspended in PBS pH 7.4, and subsequently lyophilized (VirTis, Gardiner,
NY). The blank PLGA-GLU-NPs were prepared in the same manner without the dye.
Nanoparticles were also prepared using PLGA as a polymer instead of PLGA-GLU by a
similar method [214, 215, 267].

3.3.12. Characterization of Particles: Size, Polydispersity Index and Surface Charge
3.3.12.1. Dynamic Light Scattering (DLS): The size, size distribution (polydispersity
index) and surface charge (-potential) of PLGA and PLGA-GLU-NPs were analyzed by
the procedure described in section 3.3.2.1 [214, 215, 217].
3.3.12.2. Scanning Electron Microscopy (SEM): Scanning electron microscopy (SEM,
Model S-3400N, Hitachi, Japan) was used to investigate the shape and the morphology of
PLGA-GLU-NPs. The procedure for acquiring images is described in section 3.3.2.2 [214,
215, 267].

3.3.13. In-vitro Quantitative Cell Uptake of PLGA-GLU-NPs
In-vitro cell uptake of PLGA and PLGA-GLU-NPs encapsulated with Nile red by 4T1 and
MDA-MB-231 cells were evaluated in the presence or absence of genistein (10 μM and
200 μM) by flow cytometry. The treatments and the analysis is similar to the method
described in section 3.3.5. and section 3.3.7 [215, 217].
We further compared the ability of PLGA-GLU-NPs in differentiating and delivering
the encapsulated cargo to various breast cancer cells (MDA-MB-231 and MCF7) versus
non-cancer breast epithelial cells (MCF10a). PLGA-NPs and PLGA-GLU-NPs
encapsulated with 3H-labeled oleic acid were employed for this purpose. Brieﬂy, the cells
were incubated with the medium, PLGA-NPs or PLGA-GLU-NPs loaded with 3H-labeled
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oleic acid for 4 h in the presence and absence of 5% glucose at 37°C and 5% CO2. The
cell uptake was calculated by measuring radioactive counts using the liquid scintillation
counter (Beckman Coulter LS6500).

3.3.14. In-vivo Tumor Accumulation
Female BALB/c mice were used to study the tumor accumulation of surface-modified NPs
in-vivo. Allograft tumors were developed by orthotopically injecting (1.5 × 106) 4T1 mouse
breast cancer cells in 200 µL PBS under the skin through subcutaneous injection on the left
or the right flank. All subcutaneous injections were given using a 25G needle and the hair
was removed with clippers prior to injecting the tumor cells. The animals were divided into
three groups and the NPs were administered. The mice were administered polystyrene NPssurface modified with GLU, HA and PEG (4.54 × 108 NPs) through the tail vein. The NPs
contained near-infrared (IR) dye carbocyanine DiRC18 (Ex/Em 750/780 nm) for detection.
The procedure to encapsulate the IR dye into the NPs is described in section 2.3.8. The
incorporation of the dye was confirmed by spectroscopic analysis at the excitation and
emission wavelengths of 750 nm and 780 nm respectively. After injection, the mice were
imaged using reflectance and fluorescence modules at various time points (before injection,
at 4, 8, 12, 24 and 36 h) under isoflurane anesthesia. The mice were imaged using BrukerXtreme in-vivo imager at excitation/emission wavelengths of 730/790 nm. The intensity of
the fluorescent signal was normalized and quantified using Xtreme in-vivo imager
software. The perimeter of the tumor is marked by using a reflectance image.
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3.3.15. Data Analysis & Statistics
All the experiments were performed in triplicate unless specified, and the results are
expressed as mean ± SD. The variance between groups was compared using Student’s ttest, one-way or two-way ANOVA as required followed by Bonferroni's or Dunnett's posthoc multiple comparison tests (Instat, Graph Pad Software, CA).

3.4. Results
3.4.1. Physicochemical Characterization of Polystyrene NPs
To investigate the use of glucose for attaching the NPs to cancer cells using surfaceexpressed GLUT1, polystyrene NPs with surface carboxyl groups were conjugated with
GLU, HA, and PEG using EDC chemistry as represented in the Figure 3-1A. Control
polystyrene NPs with similar size range to GLU-NPs, which were conjugated with HA or
PEG on the surface, were carefully selected to rule out the role of particle size, shape,
surface functional groups (-OH), charge, and hydrophilicity on tumor accumulation. The
results of particle size, polydispersity index and zeta potential analysis of unconjugated,
GLU, HA and PEG surface-modified NPs are presented in Table 3-1 and Figure 3-1B and
C. The average particle diameter of the unconjugated NPs as recorded by DLS technique
was 113.23 ± 1.55, 224.03 ± 3.81 and 548.60 ± 25.93 nm for NPs from commercial source
representing 100, 200, and 500 nm, respectively (Table 3-1). The surface zeta potential of
the unconjugated NPs was ranging from -30 to -40 mv, attributed to the multiple surface
carboxyl groups (Table 3-1). The size of NPs was increased after conjugating to ligands.
The average diameter of NPs was altered to 247.90 ± 3.55, 243.93 ± 3.90 and 247.4 ± 77.11
nm for GLU-NPs, HA-NPs, and PEG-NPs respectively (Table 3-1). A similar pattern was
observed with NPs of other sizes (Table 3-1). The increase in hydrodynamic radii of the
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ligand conjugated NPs along with the neutralization of surface charge of carboxyl groups
is an indication of the successful conjugation of the ligands. The NPs were found to be
monodisperse as can be seen from the polydispersity index values. The results from the
SEM experiment revealed a spherical shape of the NPs with a narrow size distribution
(Figure 3-1B). Taken together, the results from the physicochemical characterization of
NPs indicates that the ligand conjugated NPs were spherical in shape, with similar size
range and surface charge (Figure 3-1 and Table 3-1).

Table 3-1: Physicochemical characterization of surface-modified NPs. The table
represents the diameter (nm), polydispersity index (PDI) and zeta potential (mV) of
polystyrene NPs. Data represent the mean ± standard deviation (n=3-4).
Groups

Diameter (nm)

PDI

ZP (mV)

Unconjugated 100 nm NPs

113.23 ± 1.55

0.02 ± 0.01

-30.47 ± 1.91

Unconjugated 200 nm NPs

224.03 ± 3.81

0.03 ± 0.02

-36.47 ± 1.25

Unconjugated 500 nm NPs

548.60 ± 25.93

0.20 ± 0.04

-40.60 ± 0.36

GLU-NPs-100 nm

125.77 ± 3.78

0.47 ± 0.03

3.13 ± 2.24

GLU-NPs-200 nm

247.90 ± 3.55

0.09 ± 0.02

2.69 ± 0.87

GLU-NPs-500 nm

580.90 ± 78.37

0.56 ± 0.05

2.00 ± 0.85

HA-NPs-200 nm

243.93 ± 3.90

0.13 ± 0.03

3.75 ± 8.50

PEG-NPs-200 nm

247.4 ± 77.11

0.12 ± 0.01

7.46 ± 5.39
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Synthesis and Physicochemical Characterization of NPs
A. Scheme for synthesis of NPs using EDC chemistry
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B. Scanning electron micrographs of surface modified NPs
a. GLU-NPs

c. PEG-NPs

b. HA-NPs
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C. Zeta potential of surface modified NPs
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Figure 3-1: Synthesis and physicochemical characterization of polystyrene NPs. (A)
Scheme for the synthesis of surface-modified (GLU/HA/PEG) NPs using EDC chemistry.
(B). Scanning electron micrograph confirming the spherical morphology and size
distribution of GLU-NPs (a), HA-NPs (b) and PEG-NPs (c) in the nanometer range. (C).
Zeta potential (mV) of GLU-NPs (a), HA-NPs (b) and PEG-NPs (c). Data represent the
mean ± standard deviation (n=3-4).
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The functional competence of GLU-NPs to bind to GLUT1 was assessed using
human RBCs. Human RBCs heavily express GLUT1 on their surface and are expected to
bind to GLU-NPs (chapter II, section 2.4.2). NPs modified with HA or PEG did not bind
to the human RBCs when incubated for a period of 4 h at 37°C and 100 RPM (Figure 21A, chapter II). However, GLU-NPs were able to bind to the surface of RBCs in a
concentration-dependent manner (Figure 3-2).
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Figure 3-2: In-vitro binding of GLU-NPs to RBCs. Increasing amounts of fluorescent
5

GLU-NPs (2.5 x 106-1 x 109) were incubated with 1 x 10 RBCs for a period of 4 h
followed by centrifugation at 800g to separate the RBCs bound with the NPs. The RBCs
were washed 4 times and the number of NPs bound to RBCs was quantified as relative
fluorescence units (RFU) by measuring fluorescence at excitation/emission wavelengths
of 580/605 nm using a fluorimeter. Data represent the mean ± standard deviation (n=3-4).
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3.4.2. GLU-NPs were Internalized into Vesicles by Various Cancer Cells
We have studied the ability of GLU-NPs as a drug delivery vehicle to enter various cancer
cells including MDA-MB-231, NCI-H226, LnCAP, and SKMEL-2 cells. Polystyrene NPs
with neutral surface charge (HA-NPs) failed to enter the cells (Figure 3-3A). However,
when the surface of the NPs was modified with glucose (GLU-NPs), breast cancer cells
internalized a significantly higher number of NPs (Figure 3-3B). The GLU-NPs entered
the cell as a distinct perinuclear vesicle (Figure 3-3C), which might be indicative of the
involvement of endocytosis. Similar results were confirmed with cells representing
multiple cancer types: lung cancer (Figure 3-3D), prostate cancer (Figure 3-3E) and
melanoma (Figure 3-3F). The specificity of GLU-NPs entering cancer cells was confirmed
by both flow cytometry in addition to fluorescence microscopy. GLU-NPs and HA-NPs
loaded with similar physicochemical characteristics except for the surface ligand (Figure
3-1 and Table 3-1) were incubated with MDA-MB-231 cells. At different time periods, the
amount of fluorescence detected inside cells was quantified. GLU-NPs (~200 nm) on
average demonstrated ~ 25 (at 0.5 h), 17 (at 1 h), 15 (at 2 h) and 10 (at 4 h) folds higher
cell uptake than HA-NPs (Figure 3-4A).
Not only the internalization of GLU-NPs was established with multiple cancer cells,
but the phenomenon was also validated with GLU-NPs of various sizes (~100 nm, 200 nm,
and 500 nm) as quantified by flow cytometry (Figure 3-4B). An equal number of particles
were added to cells for comparison. The efficiency of internalization was determined as
relative fluorescence intensity (RFI) using flow cytometry (Figure 3-4B). The GLU-NPs
with around 500 nm in diameter showed the delivery of larger fluorescent cargo into cancer
cells compared to the smaller NPs (Figure 3-4B). This may be due to the observation that
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the fluorescent intensity of GLU-NPs with 500 nm diameter was higher compared to 200
nm and 100 nm. After normalizing the relative fluorescence intensity of NPs, the data were
plotted as a relative number of particles entered per cell (Figure 3-4C). The NPs with
around 100 nm in diameter were more efficient in entering the cancer cell in numbers
compared to larger particles. The number of NPs entering the cell increased with increasing
the incubation time from 0.5-4 h (Figure 3-4C).

Cell uptake of NPs by cancer cells
C. MDA-MB-231: GLU-NPs
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A. MDA-MB-231: HA-NPs
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D. NCI-H226: GLU-NPs
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F. S KMEL-2: GLU-NPs

5 µm
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Red: GLU-NPs; Green: Actin; Blue: Nucleus

Figure 3-3: In-vitro internalization of GLU-NPs by cancer cells. MDA-MB-231 cells
were incubated with HA-NPs (A) and GLU-NPs (B) for 4 h at 37°C. (C) Internalization of
GLU-NPs by MDA-MB-231 cells at higher magnification. The internalization of GLUNPs by NCI-H226 (D), LnCAP (E) and SKMEL-2 (F), After incubation (A-F), cells were
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extensively washed with PBS, fixed in 4% (w/v) paraformaldehyde, and observed under a
fluorescence or confocal microscope. The nucleus was stained with DAPI. *This
experiment was performed, and the data was generated by Pratik Muley.
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Figure 3-4: Cell uptake of surface-modified NPs by MDA-MB-231 cells. (A) MDAMD-231 cells were incubated with the GLU or HA NPs for 0.5-4 h. The uptake of surfacemodified NPs was quantified by flow cytometer by measuring the relative fluorescence
intensity (RFI) of each cell. (B) MDA-MD-231 cells were incubated with the equal number
of GLU-NPs (~ 100, 200 and 500 nm in diameter) for 0.5-4 h. The uptake of surfacemodified NPs was quantified by flow cytometer. (C) The relative number of NPs entered
the cell with respect to the time of incubation. Data represent the mean ± standard deviation
(n=3-4). *** indicates that the results are statistically significant at p < 0.001 as compared
to HA-NPs using two way-ANOVA followed by Bonferroni's multiple comparison test.
The specificity of uptake was further confirmed by using unique internal controls
within the treatment. The cells (MDA-MB-231) were incubated with a mixture of blue and
red fluorescent NPs that are specifically labeled with HA or GLU (Figure 3-5). When cells
were incubated with a mixture of red NPs labeled with HA and blue NPs labeled with GLU,
only GLU-NPs entered the cell as shown by only blue signal inside cells. When both blue
and red NPs were labeled with GLU, the vesicles represented both red and blue NPs (Figure
3-5).
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Internalization of GLU-NPs by MDA-MB-231 cells
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Figure 3-5: Internalization of GLU-NPs by MDA-MB-231 cells. MDA-MD-231 cells
were incubated with a mixture of blue and red fluorescent dyes that are specifically labeled
with HA or GLU. After incubation, cells were extensively washed with PBS, fixed in 4%
(w/v) PFA, and observed under a confocal microscope. *This experiment was performed,
and the data was generated by Pratik Muley.

3.4.3. The Internalization of GLU-NPs is Through Glucose-GLU1 Interaction
Accumulating evidence clearly demonstrates the over-expression of GLUT1 in various
cancers [145, 149-151, 153, 154, 156, 157, 163, 166, 179, 182, 186, 187, 262, 263]. The
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protein levels of GLUT1 in various cancer cells such as MDA-MB-231, OVCAR3, ID8,
HCT116, PC3, 4T1, and MCF7 indicates variable expression levels of GLUT1 depending
on the cell type with relatively lowest level observed in prostate cancer cell line (PC3) and
the highest levels observed with human colorectal cells (HCT116) among the cell lines
tested (Figure 3-6A). We further compared the protein levels of GLUT1 in breast cancer
cells (MDA-MB-231 and MCF7) with non-cancer cells (MCF10a), which reveals a
significantly higher expression levels in MDA-MB-231, followed by MCF7 as opposed to
MCF10a (Figure 3-6A). This differential expression of GLUT1 in cancer cells esp., in
MDA-MB-231 further provides evidence of GLUT1 as a target for cancer-specific drug
delivery.
We evaluated the involvement of GLUT1 transporters in the internalization of
GLU-NPs by multiple strategies. After incubation with the cancer cells for 4 h, the cells
were washed, and cell lysates were prepared. The cellular proteins that were bound to GLUNPs were pulled down by centrifuging the cell lysates. Western blot analysis of the proteins
bound to GLU-NPs identified GLUT1 as an interacting molecule. Control NPs (HA-NPs),
with similar surface functional groups (-OH) and size, which did not enter the cancer cells
further failed to interact with GLUT1 on the surface of cancer cells (Figure 3-6B and 36D(a)). Furthermore, the role of glucose-GLUT1 interaction in the internalization of GLUNPs was investigated by quantifying the internalization of GLU-NPs using flow cytometry
in the presence or absence of inhibitors of glucose-GLUT1 interaction. The cellular uptake
of GLU-NPs was reduced by 30-40 % in the presence of genistein (10 µM and 200 µM).
Moreover, cytochalasin B (200 µM) demonstrated ~50 % reduction in the cell uptake of
GLU-NPs (Figure 3-6C). The qualitative results from fluorescence microscopy confirm a
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significant reduction in the internalization of GLU-NPs in presence of genistein (Figure 36D(c)). Taken together, the data clearly indicates that the interaction of glucose from GLUNPs with the GLUT1 on cancer cells plays a role in the internalization of GLU-NPs.
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Figure 3-6: GLU-NPs interact with GLUT1 transporter. A. GLUT1 expression in
various cells (cancer and non-cancer cells) examined by immunoblotting. B. Affinitypulldown of proteins by GLU-NPs (MDA-MB-231 cells). Blots were reprobed with βtubulin as a loading control. C. MDA-MB-231 cells were pre-incubated with the genistein
(10 µM and 200 µM) or cytochalasin B (200 µM). After 30 min of incubation, cells were
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incubated with the medium or GLU-NPs for additional 4 h. The uptake of GLU-NPs was
quantified by flow cytometer and the percent inhibition was calculated relative to GLUNPs uptake. The data is represented as % inhibition of the uptake with respect to GLU-NPs
without inhibitors. Data represent the mean ± standard deviation (n=3-4). D. Internalization
of NPs by MDA-MB-231 cells HA-NPs (a), and GLU-NPs (b) in the presence of genistein
(GLU-NPs) (c). *The data in the figure 3-6D was generated by Pratik Muley.

3.4.4. GLU-NPs Utilize Caveolae-mediated Endocytosis for Internalization
Once it was established that GLU-NPs are internalized by induced GLUT1-mediated
endocytosis, specific pathways involved in the process of endocytosis were identified using
a panel of pharmacological inhibitors. The concentrations (μM) used were selected from
the literature and optimized to avoid cytotoxicity with the cell line tested [105, 265, 268,
269]. The internalization of fluorescent GLU-NPs by MDA-MB-231 cells was quantified
using flow cytometry in the presence or absence of the inhibitors. The data is represented
as percent inhibition of internalization (calculated from the MFI) of GLU-NPs by the
inhibitors (Figure 3-7A). Dynasore, an inhibitor of both clathrin and caveolae-mediated
endocytosis prevented the uptake of GLU-NPs by ~63 %. In contrast, rottlerin, a
macropinocytosis inhibitor showed only very minimal (20%) inhibition on the uptake of
GLU-NPs (Figure 3-7A). Nocodazole depicted ~40-45% inhibition of the uptake and
subsequent internalization (Figure 3-7A). Nocodazole is an inhibitor of polymerization of
actin and microtubule cytoskeleton, which is necessary for endocytosis. More specifically,
inhibitors of caveolae-mediated endocytosis such as genistein, cytochalasin B (Figure 36C) and nystatin (Figure 3-7A) inhibited the uptake of GLU-NPs, which is further
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confirmed by visual inspection using fluorescence microscopy (Figure 3-6D). In addition
to caveolae-mediated endocytosis inhibitor, chloroquine an inhibitor of clathrin-mediated
endocytosis also showed around ~45% reduction in the uptake of GLU-NPs. These results
demonstrate that caveolae-mediated endocytosis could play a predominant role in the
internalization of GLU-NPs, with a minor contribution by clathrin-mediated endocytosis.
After internalization through endocytosis, GLU-NPs were localized in the lysosomes as
shown by co-localization studies using a lysosomal marker (Lamp-1-GFP) (Figure 3-7B).
The images were collected by confocal microscopy.
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Internalization and localization of GLU-NPs by cancer cells
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Figure 3-7: Internalization and localization of GLU-NPs by MDA-MB-231 cells. (A)
MDA-MB-231 cells were pre-incubated with various pharmacological inhibitors of major
endocytosis pathway(s). After 30 min of incubation with or without inhibitors, cells were
incubated with medium or GLU-NPs for additional 4 h in presence or absence of inhibitors.
The uptake of GLU-NPs was quantified using flow cytometer by measuring the mean
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fluorescence intensity (MFI) of each cell and the percent inhibition was calculated relative
to GLU-NPs uptake without inhibitors. Data represent the mean ± standard deviation (n=34). (C) Localization of GLU-NPs in the lysosomal compartments using Lamp1 (lysosomalassociated membrane protein 1) tagged with a green fluorescent protein (GFP). *The data
in the figure 3-7B was generated by Pratik Muley.

3.4.5. Preparation and Characterization of PLGA-GLU Polymer and PLGA-GLU-NPs
After establishing the proof-of-concept using polystyrene NPs that over-expressed GLUT1
on cancer cells could be targeted for the delivery of NPs by induced-endocytosis, the
concept was further confirmed using the most popular nanoparticle-based drug delivery
system PLGA-NPs. For this purpose, we have conjugated GLU at the carboxyl-terminal of
the PLGA-RG-653H polymer using the EDC/NHS chemistry. The conjugation of GLU to
PLGA was confirmed by FTIR, and NMR spectroscopy. The FTIR spectrum of GLU at
about 3300 cm−1 region was characteristic of O-H stretching vibration. The peaks at 1000–
1100 cm−1 were characteristic of -C-O and -C-N stretching vibrations, whereas the FTIR
spectrum of PLGA shows a bimodal peak of aliphatic CH2 group at 2900-2800 cm−1. The
FTIR spectrum of synthesized PLGA-GLU, shows a characteristic peak at ~3300 cm−1,
~1700 cm−1 (-C=O), and bimodal peaks at 2900-2800 cm−1 characteristic of C-H2 stretch
vibration (Figure 3-8A). The NMR spectrum of GLU displayed characteristic peaks of
GLU at 8.09 ppm (-OH), 7.16 ppm (anomeric -OH), 5.07 ppm (-NH2), 3.57 ppm ( -CH and
-CH2), 3.14 ppm (anomeric -CH) and 2.83 ppm (-CH). The NMR spectrum of PLGARG653H showed characteristic peaks at 5.2 ppm (-CH), 4.91 ppm (-CH2) and 1.43 ppm (CH3). The NMR of PLGA-GLU polymer shows the chemical shift at 8.1 ppm which
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confirms the presence of the amine NH proton. The consistency of synthesized PLGAGLU from batch to batch was assessed by FTIR and proton NMR analysis. The polymers
were further characterized by PXRD analysis. The XRD spectrum indicates that both
polymers were predominantly amorphous in nature (Figure 3-8C) with no distinct peaks of
crystallinity observed. This indicates that the synthetic modification did not alter the
polymer characteristics.
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Figure 3-8: Synthesis and characterization of PLGA-GLU. (A) FTIR spectrum of GLU,
PLGA-RG653H, and PLGA-GLU. (B). The 1H-NMR spectrum of GLU, PLGA-RG653H,
and PLGA-GLU in DMSO-d6 (C) X-ray diffraction spectrum of PLGA-RG653H and
PLGA-GLU suggesting the amorphous nature of the polymers.
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PLGA-GLU-NPs were prepared encapsulated with Nile red or 3H-labeled oleic
acid. PLGA-GLU particles were spherical in shape with an average diameter of 397.30 ±
52.47 nm (Figure 3-9B) as shown by DLS-technique. The charge on PLGA-NPs was
slightly negative (= -5.23) (Figure 3-9A), whereas NPs prepared with PLGA-GLU were
slightly positive (= 6.45), indirectly indicating the availability of glucose at the surface
(Figure 3-9B). PLGA-GLU particles were spherical in shape as shown by the SEM image
(Figure 3-9C). PLGA and PLGA-GLU particles prepared without the dye were utilized as
control/blank particles.
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Physicochemical Characterization of PLGA and PLGA-GLU-NPs
A. PLGA-NPs

B. PLGA-GLU-NPs

C. S canning electron micrograph
of PLGA-GLU-NPs

Figure 3-9: Physicochemical characterization of NPs. Particle size (nanometers)
represented as % intensity and surface zeta potential (ζ-potential) represented as total
counts of PLGA-NPs (A) and PLGA-GLU-NPs (B). (C) Scanning electron micrograph of
PLGA-GLU-NPs.
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3.4.6. PLGA-GLU-NPs are Highly Efficient Cancer-targeted Drug Delivery System
NPs loaded with Nile red (lipophilic dye) were incubated with 4T1 (mouse) and MDAMB-231 (human) breast cancer cells. The amount of Nile red delivered per cell was
quantified using a flow cytometer. As a delivery system, PLGA-GLU-NPs were able to
deliver 3.5-4-fold higher cargo (Nile red) to 4T1 cells compared to PLGA-NPs (Figure 310A(a). Similarly, around 3-fold enhanced delivery of the encapsulated dye was observed
after GLU conjugation on PLGA in case of MDA-MB-231 cells (Figure 3-10B(a).
Consistent with the previous results (Figure 3-6C), incubating 4T1 cells, with genistein
reduced the uptake of PLGA-GLU-NPs by ~50 % and ~70% at concentrations of at 10 µM
and 200 µM, respectively (Figure 3-10A(b)). In the case of MDA-MB-231 cells, 10 µM
and 200 µM of genistein reduced the cellular uptake of PLGA-GLU-NPs by ~30 % and 60
%, respectively (Figure 3-10B(b)). The above results clearly demonstrate that PLGA-GLUNPs are highly efficient in delivering the cargo to cancer cells, possibly through their
interaction with GLUT1 transporter protein.
The specificity of PLGA-GLU-NPs in delivering the cargo to cancer cells versus
non-cancer cells was evaluated by loading the NPs with 3H-labeled oleic acid. The
internalized cargo was quantified using a liquid scintillation counter. Three cell lines with
variable expression levels of GLUT1 were selected: MDA-MB-231 cells with the highest
expression, followed by MCF7 cells and MCF10a cells. MCF10a cells are non-cancerous
human breast epithelial cells with low expression of GLUT1. As shown in Figure 3-10C,
PLGA-NPs failed to differentiate cancer versus non-cancer cells. Similar to the previous
experiment with Nile red (Figure 3-10A(a) and 3-10B(a)), PLGA-GLU-NPs were highly
efficient in delivering the cargo to cancer cells; ~3 folds higher compared to PLGA-NPs

117
with MDA-MB-231 cells. More importantly, glucose conjugation to the polymer enabled
the particles to differentiate cancer versus non-cancer cells (MCF10a) based on the level
of expression of GLUT1 transporter (Figure 3-10C). This becomes essential while
targeting the NPs specifically to cancer cells and thereby avoiding toxicity to normal cells.
The binding and uptake of PLGA-GLU-NPs were competed out with very high glucose in
the incubation buffer (50 mM PB with 5% glucose). The presence of a very high
concentration of glucose not only compromised their ability for the intracellular delivery
of large quantities of the cargo but also disabled the NPs to differential cancer vs noncancer
cells (Figure 3-10D).
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Figure 3-10: Cancer-targeted uptake of PLGA-GLU-NPs. 4T1 (A) and MDA-MB-231
(B) cells were incubated with the following groups (i) PLGA-NPs-NR (iii) PLGA-GLUNPs-NR for 2 and 4 h in the presence or absence of genistein (10 µM and 200 µM). The
extent intracellular NPs was quantified by flow cytometer by measuring the mean
fluorescence intensity (MFI) of each cell and the percent inhibition was calculated relative
to PLGA-GLU-NPs-NR uptake without genistein. NR stands for Nile red. (C) MDA-MB231, MCF7, and MCF10a cells were incubated with PLGA-NPs and PLGA-GLU-NPs
loaded with 3H-labeled oleic acid in the presence or absence of 5 % glucose. The
internalized cargo was quantified using a liquid scintillation counter. Data represent the
mean ± standard deviation (n=3-4). * and *** represents that the values are statistically
significant at p ≤ 0.05 and p ≤ 0.001, respectively calculated using two-way ANOVA
followed by Bonferroni's multiple comparison test. *The data in the figure 3-10C and D
was generated by Pratik Muley.

3.4.7. GLU-NPs Demonstrate Increased Tumor Accumulation
Once the concept of cancer-specific delivery of GLU-NPs was established in-vitro, we
studied the tumor accumulation of GLU-NPs by live mouse imaging. In order to detect and
quantify the NPs for in-vivo studies, the polystyrene NPs (~200 nm in diameter) were
loaded with near IR dye DiRC18 (section 2.3.8). Both the polymer and entrapped dye are
highly hydrophobic, as there was no leakage of the dye from the particles and the
combination has been used before for in-vivo analysis [217, 220]. The incorporation of the
dye was confirmed by spectroscopic analysis at the excitation and emission wavelengths
of 750 nm and 780 nm, respectively.
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The mice with subcutaneous tumors developed using allogenic 4T1 cells were
divided into three groups and GLU, HA and PEG-modified polystyrene NPs containing
carbocyanine DiRC18 (4.54 × 108 particles/mouse) were injected through the tail vein. The
HA and PEG NPs were employed as control (Figure 3-11B). The extent of GLU-NPs
circulating in the body and targeted to the tumor was significantly higher as seen from the
imaging results (qualitative) than HA-NPs or PEG-NPs (Figure 3-11B) at 4, 8, 12, 24 and
36 h post-injection. Quantitative results from in-vivo imaging depict GLU-NPs
accumulated in higher amounts (~2-4 fold) (at p < 0.05 and p < 0.001) in the tumor as
opposed to the HA-NPs or PEG-NPs at various time periods post-injection (8, 12, 24 and
36 h injection (Figure 3-12).
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Figure 3-11: In-vivo tumor accumulation of surface-modified NPs. (A) Scheme for invivo tumor accumulation of NPs. The mice were inoculated with 4T1 (1.5×106) breast
cancer cells via subcutaneous injection. GLU, HA and PEG NPs containing DiRC18
(4.54×108 particles/mouse) were injected through tail-vein on day 15 post tumor cell
inoculation. The mice were anesthetized using isoflurane before imaging at various
predetermined time points using Bruker in-vivo imager (B). The scale represents
normalized intensities. The red circle indicates the tumor site identified by the reflectance
image. In the figure, the fluorescent images were overlapped on reflectance images of the
mice.
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Figure 3-12: Quantification of tumor accumulation of surface-modified NPs. BALB/cJ
mice (n=4) inoculated with 4T1 tumors, were intravenously injected (100 μl) through tail
vein GLU, HA, and PEG-NPs at 4.54×108 particles/mouse. The mice were anesthetized
using isoflurane and imaged at 4, 8, 12, 24 and 36 h post-injection. The accumulation of
NPs in the tumor was quantified after normalizing the mean fluorescence intensities (MFI)
from the images using the Bruker-MI software. The data are plotted as mean ± standard
deviation (n=4 mice). *, *** indicates that the results are statistically significant at p < 0.05
and p < 0.001, respectively as compared to HA-NPs, whereas § indicates significant
differences at p < 0.001 as compared to PEG-NPs calculated using two way-ANOVA
followed by Bonferroni's multiple comparison test.

3.5. Discussion
The current approaches for cancer-targeted drug delivery primarily focus on utilizing
receptors that are over-expressed in cancer tissue as targets to deliver a large cargo of drugs
using nanocarriers [65, 127]. Some of the challenges in this strategy have been the
variability in receptor expression levels between patients and the complexity of the ligands
utilized for the receptors. The key parameters for the design of a successful cancer-targeted
drug delivery system include: (i) the availability of molecular targets that are differentially
expressed on cancer cells, (ii) the accessibility of the receptor for anchoring the delivery
system, (iii) initiation of appropriate signaling for the internalization of nanocarriers, and
(iv) the feasibility of the approach for in-vivo system [270-272]. In this study, we have
investigated the feasibility of glucose transporter (GLUT1), which is over-expressed in
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multiple cancer types, as a target for delivering nanocarriers (GLU-NPs) with respect to
the above key parameters.
Recently, nutritional transporters, which are over-expressed in multiple cancer
types (e.g.; GLUT1 and LAT1) are emerging as targets for new drug development and drug
delivery systems [273-275] [145, 182, 186, 276]. The recent interest is based on the
following reasons: (i) Transporters are consistently over-expressed in multiple cancers with
a strong positive correlation between the expression levels and the invasiveness of cancer
along with poor prognosis for patients [277, 278]. (ii) The expression levels of transporters
between patients and within the same patient during various stages of cancer are less
variable as compared to the receptors [260]. (iii) Most of the ligands for receptors are
macromolecules, whereas in case of transporters they are small molecules, which are
structurally stable and easy for chemical modification(s) and conjugation to nanocarriers.
(iv) Being hydrophilic small molecules, the nutrient ligands do not induce immune
recognition/response unlike larger complex ligands for receptors.
Due to the consistency in over-expression of GLUT1 in number of cancer types
along with its proven clinical utility as a target for cancer imaging using

18

F-fluoro-2-

deoxy-D-glucose (18-FDG) [139, 167, 174, 279], in this study, GLUT1 was selected as an
active target for the delivery of NPs using glucose as a ligand (GLU-NPs). GLUT1 is the
most ubiquitous, extensively studied glucose transporter among the 14 members of the
GLUT family and critical for the uptake of glucose in cancer cells. GLUT1 is overexpressed in a number of cancer types and its expression is also associated with increased
malignant potential, tumor differentiation, poor prognosis, poor overall survival, and
invasiveness. This overexpression of GLUT1 in various cancers is utilized for cancer
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management. Specifically, GLUT1 is expressed in 42% of breast tumors with increased
expression in cancers of higher grade and proliferative activity as compared to noncancerous tissues. This suggests that GLUT1 is a prognostic indicator and a potential
therapeutic target in tumors
The conjugation of glucose on the surface of NPs (GLU-NPs) was designed
carefully to allow the necessary hydroxyl groups available for binding to GLUT1 protein.
To retain high affinity towards GLUT1, glucose requires the presence of free hydroxyl
groups at the carbon 1, 4 and 6 to form hydrogen bonds with the transmembrane alphahelices of GLUT1 [141, 276]. The amino group of 2-amino-2-deoxy-D-glucose (GLU) was
employed to conjugate to the NPs and binding was confirmed using human RBCs as a
model, which expresses as high as 10 % of their surface proteins as GLUT1 (Figure 3-2)
[143].
When incubated with MDA-MB-231 breast cancer cells, GLU-NPs were
internalized into vesicular compartments in larger numbers (Figure 3-3B-F) compared to
NPs conjugated with hydroxylamine (HA-NPs) (Figure 3-3A). The cellular internalization
of NPs mostly depends on the size, shape, surface charge and surface functional groups
[46, 245, 246] of the particles. We have employed hydroxylamine modified NPs (HA-NPs)
with similar size, shape, and surface hydroxyl groups as a control to rule out the role of
above physicochemical characteristics in the internalization of GLU-NPs (Figure 3-1 and
Table 3-1). GLU-NPs demonstrated ~25 and 15 folds higher cell uptake at 0.5 h and 1 h of
incubation time, respectively and ~10 folds after 2 and 4 h of incubation compared to HANPs (Figure 3-4A). Similarly, the time-dependent uptake of glucose conjugated iron oxide
nanoparticles was demonstrated previously in breast cancer cells (MDA-MB-231) [179].
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The internalization and localization in the intracellular vesicles were consistent among
multiple cancer types: lung cancer, human prostate cancer and human malignant melanoma
cells (Figure 3-3D-F). The role of glucose on NPs and its interaction with GLUT1 on cancer
cells for the internalization of GLU-NPs was confirmed using affinity pulldown assays and
competitive inhibitors of GLUT1 (Figure 3-6B and C). Affinity pulldown assay with GLUNPs identified GLUT1 as a protein that interacts with GLU-NPs. HA-NPs with similar
surface functional group and size that did not enter the cancer cells (Figure 3-6B) failed to
interact with GLUT1. Furthermore, GLUT1 inhibitors such as genistein and cytochalasin
B reduced the uptake of GLU-NPs into MDA-MB-231 cells by 40-50 % (Figure 3-6C).
Taken together, the data from the above in-vitro experiments indicate that GLU-NPs
represent efficient nanocarriers for the delivery of cargo (drugs/imaging agents) to cancer
cells and are internalized through their interaction with GLUT1 on cancer cells.
Polystyrene particles were selected for their precise physicochemical properties to
establish proof-of-concept and preliminary mechanistic studies. However, the feasibility
of this approach for drug delivery for cancer was further evaluated using PLGA NPs, which
are the most commonly used polymeric particles for drug delivery. For this purpose, the
polymer PLGA was modified by conjugating with glucose (PLGA-GLU) (Figure 3-8 and
3-9). PLGA polymers are excellent carriers for drug delivery with several advantages:
approved by FDA for human use, biodegradable, biocompatible, possess the ease of surface
modifications, proven to a delivery variety of molecules such as small and macromolecules and demonstrate the sustained release of the cargo [280, 281]. Similar to
polystyrene NPs, internalization studies with PLGA-GLU-NPs showed increased delivery
(~3-4 folds) of cargo (Nile red) or (3H-labeled oleic acid) to cancer cells compared to

127
PLGA-NPs without glucose (Figure 3-10). Importantly, PLGA-GLU-NPs differentiated
cancer (MDA-MB-231, MCF7) and non-cancer (MCF10a) cells based on their GLUT1
expression levels (Figure 3-10C and D). In contrast, PLGA-NPs without glucose failed to
differentiate the above cells (Figure 3-10C and D). The ability to deliver the encapsulated
cargo more specifically to cancer cells is essential in avoiding the toxicity to normal cells
when loaded with chemotherapeutic drugs. Consistent with the previous results with
polystyrene NPs (Figure 3-6C and D), competitive inhibitors of glucose-GLUT1
interaction, such as genistein and 5 % glucose (Figure 3-10C and D), disabled the PLGAGLU-NPs to specifically target cancer cells that are expressing high GLUT1 protein.
The ability of the cell surface receptors to undergo endocytosis after ligand binding
has been the key element for ligand-based active targeting strategies for drug delivery. In
contrast to receptors, transporters, including GLUT1, deliver their ligands across the
membrane using transmembrane protein channels. In this study, we have established that
nutrient transporters such as GLUT1 could be induced to signal for endocytosis when the
bound ligand cannot be passed through the channel. This phenomenon is also recently been
observed by other groups [274]. We have demonstrated that GLU-NPs, when interacted
with GLUT1, were internalized predominantly by caveolae-mediated endocytosis with
minor contribution by clathrin-mediated mechanisms as a minor pathway (Figure 3-7).
Most of the materials internalized by endocytosis are sorted to either hydrolytic lysosomal
compartments [65, 178, 265, 268, 269, 282] or enter Golgi apparatus for recycling. GLUNPs were distributed into lysosomal compartment systems after 4 h of incubation as shown
by their co-localization to lysosomal marker protein Lamp1. The cargo carried by these
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NPs is expected to be released in the lysosomes and then potentially enter cytosol (Figure
3-7B) as shown with many other nanocarriers entering the lysosomes [283-286].
To advance the in-vitro potential of GLU-NPs as a drug delivery vehicle for cancer,
the final challenge is to prove its feasibility in an in-vivo system. The two key parameters
for the success of intravenously injected cancer-targeted nano-drug delivery are their
ability to remain in circulation to leak through tumor vasculature, accumulation and
retention in the tumor through their interaction with the target receptor/transporter. In
chapter II, we have clearly demonstrated that GLU-NPs have longer circulation time in
mice than PEGylation, which is the current state-of-art technology for enhanced circulation
of NPs. This was demonstrated through multiple mechanisms; reduced opsonization
(Figure 2-6) and hitchhiking on RBCs (Figure 2-7). The increased circulation time of
GLU-NPs was achieved without altering the biodistribution pattern of NPs in various
organs as compared to PEG-NPs (Figure 2-8B). We have also demonstrated that GLU-NPs
could interact with GLUT1 on RBCs in-situ during circulation. The reduced clearance of
GLU-NPs could potential provide an opportunity to leak through tumor vasculature due to
their unique anatomical anomalies of larger fenestrations.
The accumulation of GLU-NPs in the tumor was assessed using a syngeneic mouse
breast cancer model using 4T1 cells. NPs with around 200 nm in diameter were selected
for the study based on the observation that 100–200 nm demonstrated enhanced tumor
accumulation as compared to the size of NPs < 100 and >200 nm [68] [287]. GLU-NPs
clearly demonstrated significantly enhanced tumor accumulation as compared to the HA
and PEG-NPs (Figure 3-11B and 3-12). The enhanced accumulation in the tumor observed
could be due to multiple factors: (i) increased circulation time; (ii) passive targeting using
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EPR effect, and (iii) active targeting through GLUT1 transporters. Additionally, the
enhancement of tumor targeting and circulation could be due to the neutral to ±10 mV
surface charge of GLU-NPs, in contrast to charged particles that are cleared quickly by the
immune system [67, 288]. A similar strategy has been demonstrated by Shan et al. using
γ-Fe2O3 nanoparticles coated with dimercaptosuccinic acid and modified with 2-deoxy-Dglucose (γ-Fe2O3@DMSA-DG NPs) for in-vivo tumor diagnosis using 18F-fluoro-2-deoxyD-glucose (FDG) in positron emission tomography [186, 289]. Another study using 2deoxy-D-glucose-modified nano-drug delivery system demonstrated efficient glioma
treatment and simultaneous targeting to the blood-brain barrier and glioma cells [181]. The
results from this study demonstrate the ability of GLU-NPs not only for drug delivery but
also for tumor imaging and diagnosis.

3.6. Conclusions
In conclusion, through a proof-of-concept study, the feasibility of GLUT1 transporters as
a novel target for cancer-targeted delivery has been demonstrated. GLU-NPs provide an
exciting option for cancer-targeted drug delivery or imaging through multiple advantages:
(i) GLUT1 is differentially over-expressed in multiple cancer types, (ii) GLUT1 is
expressed on the surface and is accessible for binding to glucose without large linkers, (iii)
binding of GLU-NPs to GLUT1 initiates necessary signals for the internalization of GLUNPs through endocytosis, (iv) by increasing the in-vivo circulation time, GLU-NPs provide
additional benefits as a nanocarrier, and (v) glucose as a ligand is safer and is not expected
to induce major physiological or immune responses.
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4. SUMMARY AND FUTURE STUDIES
The work in this dissertation addresses two major aspects of cancer-targeted drug delivery
using nanocarriers: (i) enhancing the systemic circulation time of nanocarriers. (ii)
investigating nutritional transporter GLUT1 as an alternate to receptors as a target for
active targeting of nanocarriers.
In chapter I, we have compiled the literature and discussed the current status of
cancer-targeted drug delivery and the role of nanomedicine. The advantages and the
limitations of the nanomedicine for cancer-targeted drug delivery are addressed.
In chapter II, a recently reported concept of enhancing the circulation time of
nanocarriers by hitchhiking on RBCs was extrapolated to a clinically relevant strategy by
utilizing the natural interactions between glucose and GLUT1 transporter on the surface of
RBCs. By covalently conjugating glucose on the surface of nanoparticles (GLU-NPs),
GLU-NPs were able to bind to human RBCs in-vitro and mouse RBCs in-vivo. The
presence of plasma did not hinder the binding of GLU-NPs to human RBCs, as the strategy
is based on physiological interaction. Results from the in-vivo pharmacokinetics clearly
showed that the glucose conjugation significantly increased the circulation time of NPs in
mice. The t1/2 of GLU-NPs was ~2 folds more (~126 ± 12.56 mins) as compared to PEGNPs (75.80 ± 1.52 mins). PEG-NPs are the current state-of-the-art technology in the field
for enhancing circulation time. In addition, GLU-NPs demonstrated enhanced
accumulation (~3-6 folds) in orthotopically developed breast tumor using 4T1 cells at 12
and 24 h post 1st and 2nd injection compared to PEG-NPs. Since the interaction of glucose
with GLUT1 is physiological and occurs in-situ, the approach could be easily extended to
clinical application. Thus, this study demonstrates a practical approach of altering the

131
pharmacokinetics of nanoparticles for improved circulation and tumor accumulation by
functionalizing the NPs with glucose.
The next logical steps for this study is to test the proof-of-concept study from
polystyrene particles to more clinically relevant drug delivery systems such as liposomes,
micelles, and dendrimers. Additional studies are needed to utilize the unique property of
the interaction of GLU-NPs with RBCs, to advance them in other therapeutic applications
such as liver targeting or targeting to the brain.
In chapter III, through a proof-of-concept study, we demonstrate the ability of
GLU-NPs as an efficient nanoparticulate delivery system to differentiate between cancer
versus non-cancer cells based on their GLUT1 expression levels. The specific uptake and
subsequent internalization of GLU-NPs by cancer cells were dependent on the glucoseGLUT1 interaction as studied through competitive inhibitors of GLUT1, and affinity
pulldown assays. Unlike RBCs, the bound GLU-NPs were internalized into intracellular
vesicles in cancer cells. Mechanistic studies indicated the involvement of caveolaemediated endocytosis for the internalization. The results from in-vivo tumor accumulation
depict that the GLU-NPs localized into tumors (4T1 mouse breast cancer) in significantly
higher amounts (~2-4 folds) possibly through a combination of passive, and active
targeting. Thus, the results from this study provide the evidence on the feasibility of
employing GLUT1 as a target for active targeting of nanocarriers for cancer, which will
have implications both in drug delivery and cancer imaging.
Despite significant developments and promising application(s) of transportertargeted nano-drug delivery systems, several questions need to be studied in future research
in the field. For instance, in the case of tumor-targeted delivery, although transporters have
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shown over-expression on tumor cells, they are of importance to normal cells as well. Thus,
addressing the off-target distribution of transporter-based nano-drug delivery systems in
normal cells needs to be studied in full detail. Some reports have shown the brain
distribution of glucose conjugated nanocarriers. However, in our study, we did not find
significant levels/accumulation in the brain. More studies are needed to address the effect
of the rigidity of the particles, linker size and the availability of specific -OH groups on the
glucose on the biodistribution of GLU-NPs.
In summary, this dissertation provides considerable evidence on the ability of GLUNPs as smart nano-drug delivery systems for the in-vivo enhancement of systemic
circulation time, and tumor-targeted accumulation.
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